

**DR HABEEBULLAH
LIFE SCIENCES LIMITED**

**25th
ANNUAL REPORT
2020-21**

TABLE OF CONTENTS

CONTENTS	PAGE NO.
Corporate Information	2
Board of Directors	2
Notice of AGM	5
Director's Report	21
AOC – 1 (Financial Details of Subsidiaries / Associates / Joint Ventures)	31
MR – 3 (Secretarial Audit Report)	32
AOC – 2 (Related Party Transactions)	36
Management Discussion & Analysis Report	40
Report on Corporate Governance	43
PCS Certificate – Compliance with Corporate Governance	59
Practicing Company Secretary's Certificate on Directors	60
Remuneration Details of Directors, KMPs and Employees (as applicable)	61
CEO/CFO Certification	63
Declaration on Code of Conduct	63
Standalone Auditor's Report & Financials	64
Consolidated Auditor's Report & Financials	96

CORPORATE INFORMATION

BOARD OF DIRECTORS

Mr. K. Krishnam Raju	- Promoter & Executive Chairman (DIN 00874650)
*Dr. Mohammed Aejaz Habeeb	- Promoter – Non Executive (DIN 02265024)
*Dr. Syed Ameer Basha Paspala	- Promoter – Non Executive (DIN 07585133)
**Dr. Akka Jyothy	- Independent – Non Executive (DIN 07687798)
**Dr. T.V. Rama Krishna Murthy	- Independent – Non Executive (DIN 07688759)
Mr. B. Suryaprakasa Rao	- Independent – Non Executive (DIN 08089189)
#Ms. Aakanksha Shukla	- Independent – Non Executive (DIN 08792778)
#Mr. Y. Rama Mohan Reddy	- Independent – Non Executive (DIN 08517059)
^Dr. A.S.S.V.Srinivas	- Independent – Non Executive (DIN 06975221)
^Mr. K.N.V Narendra Kumar	- Whole time Director & CFO (DIN 09223904)

* Resigned w.e.f. 29.06.2021

** Resigned w.e.f. 02.07.2021

#Appointed w.e.f. 29.06.2021

^Appointed w.e.f. 02.07.2021

Chief Financial Officer	- Mr.K.N.V Narendra Kumar
Company Secretary	- Ms. Deepa R. Dudani
Corporate Identity Number (CIN)	- L85110TG1996PLC099198
ISIN	- INE579N01018

REGISTERED OFFICE

2-5-36/CLRD/1, Survey no. 36, Chintalmet X Roads,
Upperpally, Rajender Nagar Mandal,
Hyderabad-500048, Telangana (upto 10.08.2021)

6-3-354/13/B2, Flat.No.B2,
Suryateja Apartments,
Hindi Nagar, Punjagutta,
Hyderabad-500034, Telangana (w.e.f 11.08.2021)

STATUTORY AUDITORS

M/s. A.M. Reddy & D.R. Reddy.
Chartered Accountants
H.No: 3-6-641/1/C, 4th Floor, Street No.9
Himayatnagar, Hyderabad.500029

SECRETARIAL AUDITOR:

M/s. S.S.Reddy & Associates
Practicing Company Secretaries
Plot No. 8-2-603/23/3 & 8-2-603/23, 15,
2nd Floor, HSR Summit, Banjara Hills,
Road No. 10, Hyderabad,
Telangana - 500034

INTERNAL AUDITORS

M/s. Tungala & Co.
Chartered Accountants
Hyderabad, Telangana State, India

BANKERS

HDFC Bank Limited
Kotak Mahindra Bank
IndusInd Bank

AUDIT COMMITTEE:

Mr. B. Suryaprakasa Rao	-	Chairman
*Dr. T.V. Rama Krishna Murthy	-	Member
*Dr. A. Jyothy	-	Member
**Dr. Syed Ameer Basha Paspala	-	Member
^Dr. A.S.S.V. Srinivas	-	Member
^^Mr. Y. Rama Mohan Reddy	-	Member

*Resigned w.e.f. 02.07.2021

**Resigned w.e.f. 29.06.2021

^Appointed w.e.f. 02.07.2021

^^Appointed w.e.f. 29.06.2021

NOMINATION & REMUNERATION COMMITTEE:

*Dr. A. Jyothy	-	Chairperson
Mr. B. Suryaprakasa Rao	-	Member
*Dr. T.V. Rama Krishna Murthy	-	Member
^Dr. A.S.S.V. Srinivas	-	Chairman
^^Mr. Y. Rama Mohan Reddy	-	Member

*Resigned w.e.f. 02.07.2021

^Appointed w.e.f. 02.07.2021

^^Appointed w.e.f. 29.06.2021

STAKEHOLDER RELATIONSHIP COMMITTEE:

**Dr. T.V. Rama Krishna Murthy	-	Chairman
**Dr. A. Jyothy	-	Member
*Dr. Mohammed Aejaaz Habeeb	-	Member
Mr. B. Suryaprakasa Rao	-	Member
^Dr. A.S.S.V. Srinivas	-	Member
^^Mr. Y. Rama Mohan Reddy	-	Chairman

*Resigned w.e.f. 29.06.2021

**Resigned w.e.f. 02.07.2021

^Appointed w.e.f. 02.07.2021

^^Appointed w.e.f. 29.06.2021

INDEPENDENT DIRECTORS COMMITTEE

*Dr. T.V. Rama Krishna Murthy	-	Chairman
*Dr. A. Jyothy	-	Member
Mr. B. Suryaprakasa Rao	-	Chairman
#Ms. Aakanksha Shukla	-	Member
#Mr. Y. Rama Mohan Reddy	-	Member
^Dr. A.S.S.V. Srinivas	-	Member

* resigned w.e.f. 02.07.2021

appointed w.e.f. 29.06.2021

^ appointed w.e.f. 02.07.2021

LISTING

- 1) BSE Limited
- 2) Metropolitan Stock Exchange of India Limited

REGISTRAR & SHARE TRANSFER AGENTS

M/s. Venture Capital & Corporate Investments Private Limited
12-10-167, Bharat Nagar, Hyderabad – 500018, Telangana State, India
Contact No: 040 23818475/23818476
E-mail: info@vccilindia.com Website: www.vccilindia.com

CONTACT DETAILS

Cell : 9490424639

E-Mail : investorrelations@drhlsl.com

Website: www.drhlsl.com

NOTICE

Notice is hereby given that the 25th Annual General Meeting of members of Dr Habeebullah Life Sciences Limited will be held on Wednesday, the 15th day of September, 2021 at 9.00 a.m. through Video Conferencing/ Other Audio Visual Means (OAVM), to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt:
 - (a) The Audited Standalone Financial Statements of the Company for the financial year ended 31st March 2021, together with the Reports of the Board of Directors and Auditor's thereon.
 - (b) The Audited Consolidated Financial Statements of the Company for the financial year ended 31st March 2021, together with the Report of the Auditor's thereon.
2. To appoint a director in place of Mr. K. Krishnam Raju (DIN: 00874650) who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:**3. RE-APPOINTMENT OF MR. K. KRISHNAM RAJU (DIN:00874650) AS EXECUTIVE CHAIRMAN AND WHOLE TIME DIRECTOR OF THE COMPANY:**

To consider and if, thought fit to pass with or without modification(s), the following resolution as an Ordinary Resolution: -

“RESOLVED THAT in accordance with the provisions of Sections 196, 197, 203 and other applicable provisions, if any of the Companies Act, 2013 (“the Act”) (including any statutory modification or re-enactment thereof for the time being in force) read with Schedule V to the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2016, as amended from time to time, consent of the members of the Company be and is hereby accorded for the re-appointment of Mr. K. Krishnam Raju (DIN: 00874650) as the Executive Chairman and Whole-time Director of the Company, for a period of 3 (three) years with effect from 27.12.2021 to 26.12.2024 upon the terms & conditions of re-appointment including the payment of remuneration, perquisites & other benefits and including the remuneration to be paid in any financial year during the tenure of his re-appointment, as per the terms and conditions as recommended by the Nomination and remuneration committee in their meeting held on 29.06.2021 as set out in the Explanatory Statement annexed to the Notice convening this Meeting.”

“RESOLVED FURTHER THAT in terms of Schedule V of the Companies Act, 2013, as amended from time to time, the Board of Directors be and is hereby authorized to vary or increase the remuneration, perquisites, and allowances etc. within such prescribed limits”.

“RESOLVED FURTHER THAT in the event of losses or inadequacy of profits during his tenure the Company shall pay to Mr. K. Krishnam Raju, remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act, 2013, or such other limit as may be prescribed by the Government from time to time”.

“RESOLVED FURTHER THAT the Board be and is hereby authorised to do all acts, deeds and things including filings and take steps as may be deemed necessary, proper or expedient to give effect to this Resolution and matters incidental thereto.”

4. APPOINTMENT OF MS. AAKANKSHA SHUKLA (DIN: 08792778) AS AN INDEPENDENT DIRECTOR OF THE COMPANY:

To consider and if thought fit, to pass, with or without modifications, the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152, 160 read with Schedule IV and any other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), Ms. Aakanksha Shukla (DIN: 08792778), additional Director of the Company and who holds office upto the date of ensuing annual general meeting or the last date on which annual general

meeting is to be held whichever is earlier, who has submitted a declaration that she meets the criteria for independence as provided in Section 149(6) of the Companies Act, 2013, and the rules made thereunder, be and is hereby appointed as an Independent Director of the Company for term of five consecutive years with effect from June 29th, 2021 to June 28th, 2026.”

FURTHER RESOLVED THAT the Board of Directors be and are hereby authorized to do all such acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

5. APPOINTMENT OF MR. Y. RAMA MOHAN REDDY (DIN: 08517059) AS AN INDEPENDENT DIRECTOR OF THE COMPANY:

To consider and if thought fit, to pass, with or without modifications, the following resolution as an Ordinary Resolution:

“**RESOLVED THAT** pursuant to the provisions of Sections 149, 150, 152, 160 read with Schedule IV and any other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), Mr. Y. Rama Mohan Reddy (DIN: 08517059) as additional Director of the Company and who holds office upto the date of ensuing annual general meeting or the last date on which annual general meeting is to be held whichever is earlier, who has submitted a declaration that he meets the criteria for independence as provided in Section 149(6) of the Companies Act, 2013, and the rules made thereunder, be and is hereby appointed as an Independent Director of the Company for term of five consecutive years with effect from June 29th, 2021 to June 28th, 2026.”

FURTHER RESOLVED THAT the Board of Directors be and are hereby authorized to do all such acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

6. APPOINTMENT OF DR. A.S.S.V. SRINIVAS (DIN: 06975221) AS AN INDEPENDENT DIRECTOR OF THE COMPANY:

To consider and if thought fit, to pass, with or without modifications, the following resolution as an Ordinary Resolution:

“**RESOLVED THAT** pursuant to the provisions of Sections 149, 150, 152, 160 read with Schedule IV and any other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), Dr. A.S.S.V. Srinivas (DIN: 06975221), additional Director of the Company and who holds office upto the date of ensuing annual general meeting or the last date on which annual general meeting is to be held whichever is earlier, who has submitted a declaration that he meets the criteria for independence as provided in Section 149(6) of the Companies Act, 2013, and the rules made thereunder, be and is hereby appointed as an Independent Director of the Company for term of five consecutive years with effect from July 2nd, 2021 to July 1st, 2026.”

FURTHER RESOLVED THAT the Board of Directors be and are hereby authorized to do all such acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

7. APPOINTMENT OF MR. K.N.V. NARENDRA KUMAR (DIN: 09223904) AS DIRECTOR AND WHOLE TIME DIRECTOR OF THE COMPANY:

To consider and if thought fit, to pass, with or without modifications, the following resolution as an Ordinary Resolution:

“**RESOLVED THAT** pursuant to the provisions of Section 149 of the Companies Act, 2013 and the Rules made there under and the Articles of Association of the Company, Mr. K.N.V. Narendra Kumar (DIN: 09223904), who was appointed as an Additional Director of the Company in professional capacity on the recommendation of Nomination and Remuneration and by the Board of Directors with effect from 02.07.2021 and who holds office until the date of the ensuing Annual General Meeting or the last date on which the annual general meeting should have been held, whichever is earlier, in terms of Section 161 of the Companies Act, 2013, be and is hereby appointed as a director of the Company.

“**RESOLVED THAT** pursuant to the provisions of Sections 196, 197, 203 and any other applicable provisions of the Companies Act, 2013 and the rules made there under (including any statutory modification(s) or re-enactment thereof), read with Schedule V of the Companies Act, 2013 and pursuant to

Articles of Association of the Company, the consent of the members be and is hereby accorded for the appointment of Mr. K.N.V. Narendra Kumar (DIN: 09223904) as Whole-Time Director of the Company, for a period of 3 years commencing from 02.07.2021 at a remuneration of Rs. 70,000 p.m. and the Board of Directors be and is hereby authorized to vary or increase the remuneration, perquisites, and allowances etc. within such prescribed limits in terms of Schedule V of the Companies Act, 2013, as amended from time to time.”

“**RESOLVED FURTHER THAT** in the event of losses or inadequacy of profits in any financial year during his tenure the Company shall pay to Mr. K.N.V. Narendra Kumar, remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time.”

“**RESOLVED FURTHER THAT** the Board is hereby authorized to take all necessary steps as may be necessary to give effect to the above resolution including filing of all such necessary documents as may be required in this regard.”

8. SALE/TRANSFER/DISPOSAL OF OR OTHERWISE DILUTION OF ITS SHAREHOLDING IN THE SUBSIDIARY, KRISANI BIO SCIENCES PRIVATE LIMITED:

To consider and if thought fit, to pass, with or without modifications, the following resolution as a Special Resolution:

“**RESOLVED THAT** pursuant to Regulation 24 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and subject to such approvals, consents, sanctions and permissions, as may be necessary, consent of the members of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as “Board”, which term shall include a Committee constituted by the Board or any person(s) authorized by the Board to exercise the powers conferred on the Board by this Resolution) for sale/transfer/disposal of or otherwise dilution of its shareholding in the subsidiary, Krisani Bio Sciences Private Limited (hereinafter referred to as “KBSPL”) by further or additional allotment of new shares, at such price as per the provisions of the Companies Act, 2013.”

“**RESOLVED FURTHER THAT** for the purpose of giving effect to the above resolution the Board of Directors of the Company or a duly authorized Committee thereof, be and is hereby authorized to take such actions and to give all such directions as may be necessary or desirable and also to settle any question or difficulty that may arise in regard to the sale/transfer/disposal of or otherwise dilution of its shareholding in “KBSPL” and to do all such acts, deeds, matters and things and to execute all such deeds, documents and writings as may be necessary, desirable or expedient in connection therewith.”

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

**Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 11.08.2021**

NOTES:

1. Explanatory Statement pursuant to Section 102 of the Companies Act, 2013, in respect of the Special Business to be transacted at the 25th Annual General Meeting as set out in the Notice is annexed hereto.
2. In pursuance of Regulation 36 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings, details in respect of the Directors seeking appointment/ re-appointment at the AGM, form part of this Notice.
3. As you are aware, in view of the situation arising due to COVID-19 global pandemic, the general meetings of the companies shall be conducted as per the guidelines issued by the Ministry of Corporate Affairs (MCA) vide Circular No. 14/2020 dated April 8, 2020, Circular No.17/2020 dated April 13, 2020 and Circular No. 20/2020 dated May 05, 2020 and extended circular dated January 13, 2021. The forthcoming AGM will thus be held through video conferencing (VC) or other audio visual means (OAVM). Hence, Members can attend and participate in the ensuing AGM through VC/OAVM.
4. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by CDSL.
5. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to all members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
6. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.
7. Pursuant to MCA Circular No. 14/2020 dated April 08, 2020, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, in pursuance of Section 112 and Section 113 of the Companies Act, 2013, representatives of the members such as the President of India or the Governor of a State or body corporate can attend the AGM through VC/OAVM and cast their votes through e-voting.
8. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at [https:// www.drhlsl.com](https://www.drhlsl.com). The Notice can also be accessed from the website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and MSEI Limited i.e. www.msei.in. The AGM Notice is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM i.e. www.evotingindia.com).
9. The Register of Members and Share Transfer Books of the Company will remain closed from 09.09.2021 to 15.09.2021 (Both days inclusive).
10. Recent circular requires submission of Aadhar/PAN number by every participant in securities market. Members holding shares in demat form are, therefore, requested to submit Aadhar card/PAN details to the Depository Participants with whom they have demat accounts. Members holding shares in physical form can submit their Aadhar card/PAN details to the Company/ Registrar and Share Transfer Agents (Venture Capital Corporate Investments Private Limited)
11. Members holding shares in the same name under different ledger folios are requested to apply for Consolidation of such folios and send the relevant share certificates to Venture Capital Corporate Investments Private Limited., Share Transfer Agents of the Company for their doing the needful.

12. Members are requested to send their queries at least 10 days before the date of meeting so that information can be made available at the meeting.
13. In respect of shares held in physical mode, all shareholders are requested to intimate changes, if any, in their registered address immediately to the registrar and share transfer agent of the Company and correspond with them directly regarding share transfer/transmission/transposition, Demat/Remat, change of address, issue of duplicate shares certificates, ECS and nomination facility.
14. In terms of Section 72 of the Companies Act, 2013, a member of the Company may nominate a person on whom the shares held by him/her shall vest in the event of his/her death. Members desirous of availing this facility may submit nomination in prescribed Form-SH-13 to the Company/RTA in case shares are held in physical form, and to their respective depository participant, if held in electronic form.
15. Members holding shares in the electronic form are requested to inform any changes in address/bank mandate directly to their respective Depository Participants.
16. The company has appointed M/s. S.S. Reddy & Associates, Practicing Company Secretaries, as scrutinizer of the company to scrutinize the voting process.
17. Since securities of the Company are traded compulsorily in dematerialized form as per SEBI mandate, members holding shares in physical form are requested to get their shares dematerialized at the earliest.
18. In compliance with the aforesaid MCA Circulars and SEBI Circular dated May 12, 2020, Notice of the AGM along with the Annual Report 2020-2021 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/Depositories.
19. Since the AGM will be held through VC / OAVM, the Route Map is not annexed in this Notice.
20. The Members can join the e-AGM 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice.
21. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013, will be available for inspection at the AGM.

22. THE INTRUCTIONS FOR SHAREHOLDERS FOR REMOTE E-VOTING ARE AS UNDER:

- (i) The voting period begins on 12.09.2021 at 09.00 A.M. and ends on 14.09.2021 at 05.00 P.M. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of 08.09.2021 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242** dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

- (iv) In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants.

Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings for **Individual shareholders holding securities in Demat mode** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL	<ol style="list-style-type: none"> 1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System Myeasi. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders holding securities in demat mode with NSDL	<ol style="list-style-type: none"> 1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsd.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsd.com. Select

	<p>“Register Online for IDeAS “Portal or click at https://eservices.nSDL.com/SecureWeb/IdeasDirectReg.jsp</p> <p>3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nSDL.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting</p>
Individual Shareholders (holding securities in demat mode) login through their Depository Participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note:

Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022- 23058738 and 22-23058542-43.
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nSDL.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30

(v) Login method for e-Voting and joining virtual meeting for shareholders other than individual shareholders holding in Demat form & physical shareholders.

- 1) The shareholders should log on to the e-voting website www.evotingindia.com.
- 2) Click on “Shareholders” module.
- 3) Now enter your User ID

- a. For CDSL: 16 digits beneficiary ID,
- b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
- c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first time user follow the steps given below:

For Shareholders holding shares in Demat Form and other than individual and Physical Form	
PAN	<p>Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)</p> <ul style="list-style-type: none"> • Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	<p>Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login.</p> <p>1. If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (v).</p>

- (vi) After entering these details appropriately, click on “SUBMIT” tab.
- (vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant <DR HABEEBULLAH LIFE SCIENCES LIMITED> on which you choose to vote.
- (x) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xii) After selecting the resolution you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xiii) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

(xvi) Shareholders can also cast their vote using CDSL's mobile app "m-Voting". The m-Voting app can be downloaded from respective Store. Please follow the instructions as prompted by the mobile app while Remote Voting on your mobile.

(xvii) Facility for Non – Individual Shareholders and Custodians – Remote Voting

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the "Corporates" module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address investorrelations@drhisl.com (designated email address by company), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for Remote e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least 3 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 3 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to Company/RTA email id.
2. For Demat shareholders -, please update your email id & mobile no. with your respective Depository Participant (DP).
3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at 022- 23058738 and 022-23058542/43.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call on 022-23058542/43

23. OTHER INSTRUCTIONS:

- (i) The voting rights of shareholders shall be in proportions to the shares held by them in the paid equity share capital of the Company as on the cut-off date i.e. 08.09.2021.
 - (ii) The Scrutinizer shall after the conclusion of the Voting at the Annual General Meeting first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two (2) witnesses not in the employment of the Company and make not later than three days of conclusion of the meeting a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or person authorized by him.
 - (iii) Voting is provided to the members through e-voting and at the Annual General Meeting of the Company. A Member can opt for only one mode of voting i.e. either through e-voting or at the Annual General Meeting of the Company.
 - (iv) If a Member casts votes by both modes, then voting done through e-voting shall prevail.
 - (v) The results declared along with the Scrutinizer's Report shall be placed on the Company's website www.drhlsl.com and on the website of CDSL and will be communicated to the BSE Limited and MSEI Limited.
24. Relevant documents referred to in the accompanying Notice, as well as Annual Report are open for inspection at the Registered Office of the Company, during the office hours, on all working days up to the date of Annual General Meeting.
 25. SEBI has notified vide Notification No. SEBI/LAD-NRO/GN/2018/24 that securities of the listed companies can be transferred only in dematerialized form. In view of the above and to avail various benefits of dematerialization, members are advised to dematerialize shares held by them in physical form.
 26. The Ministry of Corporate Affairs (vide circular nos. 17/2011 and 18/2011 dated 21st April and 29th April 2011 respectively), has undertaken a 'Green Initiative in Corporate Governance' and allowed companies to share documents with its shareholders through an electronic mode. Members are requested to support this green initiative by registering/uploading their email addresses, in respect of shares held in dematerialized form with their respective Depository Participant and in respect of shares held in physical form with the Company's Registrar and Share Transfer Agents.

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)

Place: Hyderabad
Date: 11.08.2021

EXPLANATORY STATEMENT

[Pursuant to Section 102 of the Companies Act, 2013]

ITEM No. 3

RE-APPOINTMENT OF MR. K. KRISHNAM RAJU (DIN: 00874650) AS EXECUTIVE CHAIRMAN AND WHOLE TIME DIRECTOR OF THE COMPANY

Mr. K. Krishnam Raju (DIN: 00874650) was appointed as Whole-time Director of the Company for a period of 5 years from 27.12.2016 to 26.12.2021 at the Extra Ordinary General Meeting of the shareholders held through postal ballot on 08.02.2017.

Based on the recommendations of the Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on 11.08.2021, approved the re-appointment of Mr. K. Krishnam Raju (DIN: 00874650) as Executive Chairman and Whole-time Director of the Company for a term of three years commencing from 27.12.2021 to 26.12.2024 with a remuneration of Rs. 3,00,000 per month.

Accordingly, the Board of Directors recommends the passing of the above Resolution as an Ordinary Resolution set out in the item no. 3 of the notice for reappointment of Mr. K. Krishnam Raju (DIN: 00874650).

Save and except, Mr. K. Krishnam Raju, Whole-Time Director being an appointee none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

Information in accordance with Schedule V of Companies Act, 2013

I. GENERAL INFORMATION

1.	Nature of Industry: Healthcare services		
2.	Date or expected date of commencement of commercial: The Company started its trial run operations during the Financial Year 2017-18		
3.	In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable		
4.	Financial performance based on given indications :		
	Particulars	2018-19 (Amt in Rs.)	2019-20 (Amt in Rs.)
	Turnover	2,01,44,734	1,43,18,627
	Net profit/loss after Tax	(2,14,18,650)	(1,89,01,601)
			2020-21 (Amt in Rs.)
			1,29,724
			(76,97,072)
5.	Foreign investments or collaborations, if any: Not Applicable		

II. INFORMATION ABOUT THE APPOINTEE:

1.	Background Details: Mr. Kalidindi Krishnam Raju, S/o K. V. Subba Raju, aged about 62 years, is a Chartered Accountant from the Institute of Chartered Accountants of India. He practiced as a Chartered Accountant, worked in different organizations and worked as Director Finance in Visual Soft Technologies Limited, followed by promoting Krisani Wealth Management focused on financial research and Krisani Bio Sciences Private Limited in 2009 which is into design and development of New Drug Discovery including New Molecular Entity (NME).
2.	Past Remuneration: The past remuneration drawn by Mr. K. Krishnam Raju, Whole-time Director was Rs. 3,00,000/-.
3.	Recognition or awards: NA
4.	Job Profile and his suitability: Keeping the past record of Mr. K. Krishnam Raju, Whole-time Director in mind and his contribution towards the Company, it is proposed for payment of remuneration to Mr. K. Krishnam Raju, Whole-time Director Rs. 3,00,000/- per month.
5.	Remuneration proposed: As set out in the Resolutions for the item No.3 the remuneration Mr. K. Krishnam Raju has the approval of the Nomination and Remuneration Committee and Board of Directors, is within the limits specified under Schedule V of Companies Act.
6.	Comparative remuneration profile with respect to industry, size of the Company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin): Taking into consideration of the size of the Company, the profile of Mr. K. Krishnam Raju and the responsibilities shouldered on him, the aforesaid remuneration package is commensurate with the remuneration package paid to managerial positions in other companies.

Item No. 4&5

Ms. Aakanksha Shukla and Mr. Y. Rama Mohan Reddy were appointed as Additional Directors on 29th June, 2021 in terms of Section 161 (1) of the Companies Act, 2013 in the category of 'Non-Executive Independent' in terms of the Companies Act, 2013, an Additional Director shall hold office up to the date of the ensuing Annual General Meeting of the Company or the last date on which annual general meeting should have been held, whichever is earlier and be eligible for appointment to the office of a Director at General Meeting in terms of Section 160 of the Companies Act, 2013. The Company has received a notice from a member under Section 160 of the Companies Act 2013, for appointment of Ms. Aakanksha Shukla and Mr. Y. Rama Mohan Reddy for the office of Director in Independent category.

In order to ensure compliance with the provisions of Sections 149 and 152 of the Companies Act, 2013 read with Rules made there under and Schedule IV of the Act, it is proposed that approval of the shareholders be accorded for the appointment of Ms. Aakanksha Shukla and Mr. Y. Rama Mohan Reddy as 'Non-executive Independent Directors' for a term up to 5 consecutive years commencing from the date of their appointment as an Additional Director i.e.w.e.f 29th June, 2021 to 28th June, 2026.

Accordingly the Board of Directors recommends the passing of the above resolutions as an Ordinary Resolution set out in the item no.4&5 of the notice for appointment of Ms. Aakanksha Shukla and Mr. Y. Rama Mohan Reddy.

Save and except Ms. Aakanksha Shukla and Mr. Y. Rama Mohan Reddy, Independent Directors, being the appointees, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in their respective Resolutions set out in the notice.

Item No. 6

Dr. A.S.S.V. Srinivas was appointed as Additional Director on 02nd July, 2021 in terms of Section 161 (1) of the Companies Act, 2013 in the category of 'Non-Executive Independent' in terms of the Companies Act, 2013, an Additional Director shall hold office up to the date of the ensuing Annual General Meeting of the Company or the last date on which annual general meeting should have been held, whichever is earlier and be eligible for appointment to the office of a Director at General Meeting in terms of Section 160 of the Companies Act, 2013. The Company has received a notice from a member under Section 160 of the Companies Act 2013, for appointment of Dr. A.S.S.V. Srinivas for the office of Director in Independent category.

In order to ensure compliance with the provisions of Sections 149 and 152 of the Companies Act, 2013 read with Rules made there under and Schedule IV of the Act, it is proposed that approval of the shareholders be accorded for the appointment of Dr. A.S.S.V. Srinivas as 'Non-executive Independent Director' for a term up to 5 consecutive years commencing from the date of his appointment as Additional Director i.e. 02nd July, 2021 to 01st July, 2026.

Accordingly the Board of Directors recommends the passing of the above resolution as an Ordinary Resolution set out in the item no.6 of the notice for appointment of Dr. A.S.S.V. Srinivas.

Save and except Dr. A.S.S.V. Srinivas, Independent Director, being an appointee, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

Item No.7:

Mr. K.N.V. Narendra Kumar was inducted into Board as Additional Director(in executive category) of the company, with effect from 02.07.2021 pursuant to the provisions of Section 161(1) of the Companies Act, 2013 and holds the office as such up to the date of ensuing Annual General Meeting or the last date on which the annual general meeting should have been held, whichever is earlier. As per the provisions of section 160 of the Act, any such proposal ought to be approved by the members in the General Meeting.

The Board of Directors in its meeting held on 29.06.2021, subject to the approval of the Shareholders, and upon the recommendation of Nomination and Remuneration committee appointed Mr. K.N.V Narendra Kumar as Whole-time Director of the Company with effect from 02.07.2021 for a period of 3 years at a remuneration of Rs. 70,000 p.m. with liberty to the Board of directors to fix, alter or vary from time to time the terms and conditions of the said appointment including the remuneration in such manner as it may deem fit within the limits in that behalf contained in Schedule V of the said Act including any Statutory modification(s) in force or that may hereinafter be made thereto and as may be agreed by the Board of Directors and Mr. K.N.V. Narendra Kumar in this behalf.

Accordingly, the Board of Directors recommends the passing of the above Resolution as an Ordinary Resolution set out in the item no. 7 of the notice for appointment of Mr. K.N.V. Narendra Kumar.

Save and except, Mr. K.N.V. Narendra Kumar being an appointee none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

Information in accordance with schedule V of companies act, 2013

I. GENERAL INFORMATION

1.	Nature of Industry: Healthcare services		
2.	Date or expected date of commencement of commercial: The Company started its trial run operations during the Financial Year 2017-18		
3.	In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable		
4.	Financial performance based on given indications :		
	Particulars	2018-19 (Amt in Rs.)	2019-20 (Amt in Rs.)
	Turnover	2,01,44,734	1,43,18,627
	Net profit/loss after Tax	(2,14,18,650)	(1,89,01,601)
5.	Foreign investments or collaborations, if any: Not Applicable		

II. INFORMATION ABOUT THE APPOINTEE:

1.	Background Details: Mr. K.N.V. Narendra Kumar is a graduate and has an experience of 15 years in Krisnai Group of Companies in different capacities including CFO in Dr Habeebullah Life Sciences Limited.
2.	Past Remuneration: The past remuneration drawn by Mr. K.N.V. Narendra Kumar, as CFO of the Company was Rs. 70,000/- per month.
3.	Recognition or awards: NA
4.	Job Profile and his suitability: Keeping the past record of Mr. K.N.V. Narendra Kumar as CFO in mind and his contribution towards the Company, it is proposed for payment of remuneration to Mr. K.N.V. Narendra Kumar, Whole-time Director Rs. 70,000/- per month.
5.	Remuneration proposed: As set out in the Resolutions for the item No.7 the remuneration to Mr. K.N.V. Narendra Kumar has the approval of the Nomination and Remuneration Committee and Board of Directors, is within the limits specified under Schedule V of Companies Act.
6.	Comparative remuneration profile with respect to industry, size of the Company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin): Taking into consideration of the size of the Company, the profile of Mr. K.N.V. Narendra Kumar and the responsibilities shouldered on him, the aforesaid remuneration package is commensurate with the remuneration package paid to managerial positions in other companies.

As required under regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of the Directors seeking appointment/re-appointment are given as under:

Name of the Director	Mr. K. Krishnam Raju	Ms. Aakanksha Shukla	Mr. Y. Rama Mohan Reddy
Date of Birth	01.01.1959	09-03-1992	19/01/1966
Qualification	Chartered Accountant	Company Secretary	Graduate
Expertise in specific functional areas	specialize in Wealth Management focused on financial research, strategic planning and structuring the Organizations	specialize in compliances relating to preferential allotment of shares of listed and unlisted companies, mergers, IPO and buy back of shares	specialize in the field of Management, Marketing and Administration
Names of Listed entities in which the person also holds the directorship and the membership of Committees of the board	NIL	1.Palred Technologies Limited	1.Taaza International Limited 2.G.R.cables Limited 3.Sankhya Infotech Limited
Shareholding of non-executive directors:	NA	NIL	NIL
No. of Shares held in the Company	28,99,630 Equity shares	NIL	NIL
Inter se relationship with any Director	NIL	NIL	NIL

Name of the Director	Dr. A.S.S.V. Srinivas	Mr. K.N.V. Narendra Kumar
Date of Birth	11.10.1963	09.06.1977
Qualification	Post Graduate, Ph.D	Graduate
Expertise in specific functional	Specialize in in the field of Research and Development.	Specialize in finance and accounts
Names of Listed entities in which the person also holds the directorship and the membership of Committees of the board	NIL	NIL
Shareholding of non-executive directors:	NIL	NIL
No. of Shares held in the Company	NIL	NIL
Inter se relationship with any Director	NIL	NIL

ITEM NO 8:

Pursuant to the Regulation 24 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, to cease the exercise of control in Subsidiary Company requires the prior approval of the shareholders by way of a special resolution. The Company in its Board meeting held on 11.08.2021 considered and approved the proposal from the subsidiary for conversion of unsecured loans brought in by the promoters into equity shares. It is noted that the core promoters of Krisani Bio Sciences Private Limited namely Mr. K. Krishnam Raju and Mrs. K. Sarada Vijaya Kumari infused interest free unsecured loans to the tune of Rs. 6.40 crores from time to time in order to meet the business requirements of the Company. Having considered the mutual understanding and discussions of the subsidiary company and its promoters and particularly in view of the shortage of funds to repay, the Board of Dr Habeebullah Life Sciences Limited has accorded its approval for conversion of loans into equity by the subsidiary Company (Krisani Bio Sciences Private Limited) in favour of its core promoters at such price as may be decided in terms of the applicable provisions of the Companies Act, 2013. As a result of the proposed allotment of shares to the promoters by the subsidiary, the shareholding of the parent company i.e., Dr Habeebullah Life Sciences Limited in the subsidiary company will fall down to less than 50%.

Accordingly, the Board of Directors recommend passing of the above Resolution as Special Resolution as set out in item No. 8 of the Notice.

None of the Directors or Key Managerial Personnel of the Company or their respective relatives, except Mr. K. Krishnam Raju, Chairman and Executive Director and his relatives is in any way concerned or interested in the above Special Resolution set out in the Notice.

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

**Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 11.08.2021**

DIRECTORS' REPORT

Dear Members,

Your Directors have pleasure in presenting the Directors' Report and the Audited Statement of Accounts (both Standalone and Consolidated) of the Company for the Financial Year ended 31st March 2021.

1. FINANCIAL SUMMARY/HIGHLIGHTS:

The performance of the Company during the year has been as under:

(Amount in INR)

Particulars	Standalone		Consolidated	
	2020-21	2019-2020	2020-2021	2019-20
Revenue from Operations	1,29,724	1,43,18,627	1,29,724	1,43,18,627
Other Income (Including Exceptional Items)	14,77,331	15,81,825	14,77,331	15,81,825
Total Expenses	93,04,127	3,48,02,053	96,22,881	3,64,27,765
Profit Before Tax	(76,97,072)	(1,89,01,601)	(80,15,826)	(2,05,27,313)
Less: Provision for Taxation	-	-	(2,49,103)	(7,11,011)
Profit / (Loss) After Tax	(76,97,072)	(1,89,01,601)	(77,66,723)	(1,98,16,302)
Other Comprehensive Income	14,08,499	1,84,859	14,08,499	1,84,859
Total Comprehensive Income	(62,88,573)	(1,87,16,742)	(63,58,224)	(1,96,31,443)
Earning per Equity Share-	(0.42)	(1.28)	(0.43)	(1.31)
Basic & Diluted (in Rs.)	(0.42)	(1.28)	(0.43)	(1.31)

REVIEW OF OPERATIONS:

Revenue - Standalone

During the Year under the review, the Company has recorded an Income of Rs. 16.07 Lakhs and profit/ Loss of Rs. (76.97) Lakhs as against the Income of Rs. 159.00 Lakhs and profit/ Loss of Rs. (189.01) Lakhs in the previous financial year ending 31.03.2020.

Revenue – Consolidated

During the Year under the review, the Company has recorded an Income of Rs.16.07 Lakhs and profit/ Loss of Rs (77.67) Lakhs as against the Income of Rs. 159.00 Lakhs and profit/ Loss of Rs. (198.16) Lakhs in the previous financial year ending 31.03.2020.

BUSINESS UPDATE AND STATE OF COMPANY'S AFFAIRS:

The information on Company's affairs and related aspects is provided under Management Discussion and Analysis report, which has been prepared, inter-alia, in compliance with Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) regulations, 2015 and forms part of this Report.

2. IMPACT OF COVID – 19:

The COVID-19 created havoc in the world economy and severely affected the health of people at large and held the world at its standstill. Accordingly, the lockdowns that were announced from time to time across India resulting in temporary suspension of operations and temporary closure of offices and plants/manufacturing facilities of the Company in line with the government/local authorities' directions.

However, due to increase in the Covid -19 Cases in the city of Hyderabad, the Board has decided that to ensure the safety and wellbeing of its employees, workmen and all stakeholders and to prevent the spread

of COVID-19, the Company has suspended its operations since 20.06.2021 and the management will review about the reopening of centre after some time.

3. CHANGE IN THE NATURE OF THE BUSINESS, IF ANY

During the period under review and the date of Board's Report there was no change in the nature of Business.

4. RESERVES

The Closing balance of reserves, including retained earnings, of the Company as at March 31st 2021 is Rs. (3,00,83,066).

5. DIVIDEND

Since the Company is yet to start generating profits, your Directors have decided not to recommend dividend for the year.

6. MATERIAL CHANGES & COMMITMENT AFFECTING THE FINANCIAL POSITION OF THE COMPANY

There are no major material changes and commitments affecting the financial position of the Company after the end of the financial year and up to date of this report (i.e. 29.06.2021)

7. BOARD MEETINGS

The Board of Directors duly met Five (05) times during the financial year from 1st April 2020 to 31st March 2021. The dates on which the meetings were held are 29.07.2020, 14.09.2020, 13.11.2020, 02.12.2020 and 13.02.2021.

8. APPOINTMENT / RE-APPOINTMENT / RESIGNATION / RETIREMENT OF DIRECTORS /CEO/ CFO AND KEY MANAGERIAL PERSONNEL

a.) Following Appointments have taken place till the date of this report

S. No.	Name of the Director/KMP	Designation	Date
1	Ms. Aakanksha Shukla	Additional Director (Independent Category)	29.06.2021
2	Mr. Y. Rama Mohan Reddy	Additional Director (Independent Category)	29.06.2021
3	Dr. A.S.S.V. Srinivas	Additional Director (Independent Category)	02.07.2021
4	Mr. K.N.V. Narendra Kumar	Whole time Director	02.07.2021
5	Ms. Deepa R. Dudani	Company Secretary and Compliance Officer	13.02.2021

b.) Following Resignations have taken place till the date of this report

S. No.	Name of the Director/KMP	Designation	Date
1	Dr. Ameer Basha Paspala	Director	29.06.2021
2	Dr. Mohammad Aejaz Habeeb	Director	29.06.2021
3	Dr. Akka Jyothy	Independent Director	02.07.2021
4	Dr. T.V. Rama Krishna Murthy	Independent Director	02.07.2021
5	Ms. Neha Kankariya	Company Secretary and Compliance Officer	13.02.2021

The Board places on record its sincere appreciation for the services rendered by the Directors/KMP during their association with the Company.

9. REVISION OF FINANCIAL STATEMENTS

There was no revision of the financial statements for the year under review.

10. DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS

The Company has received declarations from all the Independent Directors of the Company to the effect that they are meeting the criteria of independence as provided in Sub-Section (6) of Section 149 of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Independent Directors have also confirmed that they have complied with the Company's Code of Conduct.

In terms of Regulations 25(8) of the Listing Regulations, the Independent Directors have confirmed that they are not aware of any circumstance or situation, which exists or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgment and without any external influence.

During the year, Independent Directors of the Company had no pecuniary relationship or transactions with the Company, other than sitting fees, commission and reimbursement of expenses incurred by them for the purpose of attending meetings of the Board of Directors and Committee(s).

11. FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS

Independent Directors are familiarized about the Company's operations and businesses. Interaction with the Business heads and key executives of the Company is also facilitated. Detailed presentations on important policies of the Company is also made to the directors. Direct meetings with the Chairman are further facilitated to familiarize the incumbent Director about the Company/its businesses and the group practices.

12. POLICY ON DIRECTOR'S APPOINTMENT AND REMUNERATION AND OTHER DETAILS

The assessment and appointment of Members to the Board is based on a combination of criterion that includes ethics, personal and professional stature, domain expertise, gender diversity and specific qualification required for the position. The potential Board Member is also assessed on the basis of independence criteria defined in Section 149(6) of the Companies Act, 2013 and Regulation 27 of SEBI (LODR) Regulations, 2015.

In accordance with Section 178(3) of the Companies Act, 2013 and Regulation 19(4) of SEBI (LODR) Regulations, 2015, on the recommendations of the Nomination and Remuneration Committee, the Board adopted a remuneration policy for Directors, Key Management Personnel (KMPs) and Senior Management. The Policy is attached a part of Corporate Governance Report.

We affirm that the remuneration paid to the Directors is as per the terms laid down in the Nomination and Remuneration Policy of the Company.

13. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the requirement of Section 134(3)(c) and 134(5) of the Companies Act, 2013 and on the basis of explanation given by the executives of the Company and subject to disclosures in the Annual Accounts of the Company from time to time, we state as under:

1. That in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
2. That the Directors have selected such accounting policies and applied them consistently and made judgment and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that period;
3. That the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

4. That the Directors have prepared the annual accounts on a going concern basis:
5. That the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and
6. That the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

14. INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

Pursuant to the provisions of Section 124 of the Act, Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") read with the relevant circulars and amendments thereto, the amount of dividend remaining unpaid or unclaimed for a period of seven years from the due date is required to be transferred to the Investor Education and Protection Fund ("IEPF"), constituted by the Central Government.

During the Year, no amount of dividend was unpaid or unclaimed for a period of seven years and therefore no amount is required to be transferred to Investor Education and Provident Fund under the Section 125(1) and Section 125(2) of the Act.

15. INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE SUBSIDIARIES / ASSOCIATES/ JOINT VENTURES

Krisani Bio Sciences Private Limited is the subsidiary company of Company incorporated on 10.11.2009, The Subsidiary Company has consolidated turnover of Rs. 1,29,724. The detailed financial position of the Subsidiary is provided in the Annexure- I-AOC-1

16. ANNUAL RETURN

As required pursuant to Section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014, an annual return is disclosed on the website www.drhlsl.com

17. AUDITORS

a. Statutory Auditors

The members of the Company at their Annual General Meeting held on 26th December, 2020 have appointed M/s. A.M. Reddy & D.R. Reddy, as statutory auditors of the Company for five years to hold office until the conclusion of 29th Annual General meeting of the Company to be held in the year 2025. The Auditor's Report is enclosed with the financial statements in this Annual Report. The Company has received audit report with unmodified opinion for both Standalone and Consolidated audited financial results of the Company for the Financial Year ended March 31, 2021 from the statutory auditors of the Company.

The Auditors have confirmed that they have subjected themselves to the peer review process of Institute of Chartered Accountants of India (ICAI) and hold valid certificate issued by the Peer Review Board of the ICAI.

Statutory Auditors Report

The Board has duly reviewed the Statutory Auditor's Report on the Accounts for the year ended March 31, 2021 and has noted that the same does not have any reservation, qualification or adverse remarks. However, the Board decided to further strengthen the existing system and procedures to meet all kinds of challenges and growth in the coming years.

b. Secretarial Auditor

Pursuant to the provisions of Section 134(3) (f) & Section 204 of the Companies Act, 2013, the Board has appointed M/s. S.S Reddy & Associates, Practicing Company Secretaries has undertaken Secretarial Audit of the Company for financial year ending 31.03.2021. The report of the Secretarial Auditor is enclosed herewith vide Annexure-II of this Report.

Secretarial Audit Report

The Board has duly reviewed the Secretarial Audit Report for the year ended March 31, 2021 on the Compliances according to the provisions of Section 204 of the Companies Act, 2013.

Annual Secretarial Compliance Report

The Company has filed the Annual Secretarial Compliance Report for the year 2020-2021 with the BSE Limited and Metropolitan Stock Exchange of India Limited, The report was received from a Practicing Company Secretary and filed with both the Exchanges.

c. Cost Auditor

Maintenance of cost records and requirement of cost audit as prescribed under the provisions of Section 148 (1) of the Act, are not applicable for the business activities carried out by the Company.

d. Internal Auditor

Pursuant to provisions of Section 138 read with Rule 13 of the Companies (Accounts) Rules, 2014 and Section 179 read with Rule 8(4) of the Companies (Meetings of Board and its Powers) Rules, 2014; M/s. Tungala & Co., Chartered Accountants were appointed as Internal Auditors of the Company for the Financial Year 2020-21.

Deviations are reviewed periodically and due compliance ensured. Summary of Significant Audit Observations along with recommendations and its implementations are reviewed by the Audit Committee and concerns, if any, are reported to Board.

18. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB SECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT

There have been no frauds reported by the auditor's u/s 143(12).

19. INTERNAL AUDIT AND FINANCIAL CONTROLS

The Company has adequate internal controls consistent with the nature of business and size of the operations, to effectively provide for safety of its assets, reliability of financial transactions with adequate checks and balances, adherence to applicable statutes, accounting policies, approval procedures and to ensure optimum use of available resources. These systems are reviewed and improved on a regular basis. It has a comprehensive budgetary control system to monitor revenue and expenditure against approved budget on an ongoing basis.

20. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

The Company has not given loans, Guarantees or made any investments during the year under review.

21. RELATED PARTY TRANSACTIONS

Our Company has formulated a policy on related party transactions which is also available on Company's website at www.drhlsl.com. This policy deals with the review and approval of related party transactions.

All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of business. There were no material significant related party transactions made by the Company with the Promoters, Directors, Key Managerial Personnel or the Senior Management which may have a potential conflict with the interest of the Company at large.

Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013 in the prescribed Form AOC-2 is appended as Annexure III which forms part of this Report.

All related party transactions were placed before the Audit Committee/Board for approval. Prior approval of the Audit Committee was obtained for the transactions which are foreseen and are in repetitive in nature. Members may refer to note no. 24 to the financial statement which sets out related party disclosures pursuant to INDAS-24.

22. CONSOLIDATED FINANCIAL STATEMENTS

The Consolidated Financial Statements of your Company for the year ended March 31, 2021 have been prepared in accordance with the provisions of Section 129(3) of the Companies Act and applicable Accounting Standards and form part of this report.

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with first proviso of Section 129(3) of the Companies Act read with Rule 5 of the Companies (Accounts) Rules, 2014, a separate statement containing salient features of the Financial Statements of Subsidiary Company in Form AOC-1 is appended to this report as Annexure I, which forms part of the Financial Statements. The separate Audited Financial Statements in respect of the Subsidiary are also available on the website of the Company at www.drhlsl.com.

23. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR

During the year under review no Company has become or ceased to become its subsidiary, joint venture or associate Company.

24. DISCLOSURE OF PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The particulars as prescribed under Section 134(3) (m) of the Companies Act, 2013, is provided hereunder:

A. Conservation of Energy:

Your Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible by using energy efficient computers and purchase of energy efficient equipment.

B. Research & Development and Technology Absorption:

1. Research and Development (R&D): NIL
2. Technology absorption, adoption and innovation: NIL

C. Foreign Exchange Earnings and Out Go:

Foreign Exchange Earnings: NIL

Foreign Exchange Outgo: NIL

25. COMMITTEES**(I). AUDIT COMMITTEE**

During the year, the Audit Committee is in line with the provisions of Regulation 18(1) of SEBI (LODR) Regulations with the Stock Exchanges read with Section 177 of the Companies Act, 2013 are included in the Corporate Governance report, which forms part of this report.

(II). NOMINATION AND REMUNERATION COMMITTEE

During the year, the Nomination and Remuneration Committee is in line with the provisions of Regulation 19(1) of SEBI (LODR) Regulations with the Stock Exchanges read with Section 178 of the Companies Act, 2013 are included in the Corporate Governance report, which forms part of this report.

(III). STAKEHOLDERS RELATIONSHIP COMMITTEE

During the year, the Stakeholders Relationship Committee is in line with the provisions of Regulation 20 of SEBI (LODR) Regulations with the Stock Exchanges read with Section 178 of the Companies Act, 2013 are included in the Corporate Governance report, which forms part of this report.

26. VIGIL MECHANISM/WHISTLE BLOWER POLICY

In pursuant to the provisions of Section 177(9) & (10) of the Companies Act, 2013 read with Regulation 22 of SEBI (LODR) Regulations, 2015, a vigil Mechanism for Directors and employees to report genuine

concerns has been established. It also provides for necessary safeguards for protection against victimization for whistle blowing in good faith.

Vigil Mechanism Policy has been established by the Company for directors and employees to report genuine concerns pursuant to the provisions of section 177(9) & (10) of the Companies Act, 2013. The same has been placed on the website of the Company.

27. CORPORATE SOCIAL RESPONSIBILITY (CSR, COMPOSITION OF CSR COMMITTEE AND CONTENTS OF CSR POLICY)

Since your Company does not have net worth of Rs. 500 Crore or more or turnover of Rs. 1000 Crore or more or a net profit of Rs. 5 Crore or more during the financial year, section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is not applicable and hence the Company need not adopt any Corporate Social Responsibility Policy.

28. PUBLIC DEPOSITS

Your Company has not accepted any deposits falling within the meaning of Sec.73, 74 & 76 of the Companies Act, 2013 read with the Rule 8(v) of Companies (Accounts) Rules 2014, during the financial year under review.

29. SIGNIFICANT & MATERIAL ORDERS PASSED BY COURTS / REGULATORS / TRIBUNALS

There are no significant and material orders passed by the regulators /courts that would impact the going concern status of the Company and its future operations.

30. DISCLOSURE OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS

The Internal Financial Controls with reference to financial statements as designed and implemented by the Company are adequate. The Company maintains appropriate system of internal control, including monitoring procedures, to ensure that all assets are safeguarded against loss from unauthorized use or disposition. Company policies, guidelines and procedures provide for adequate checks and balances, and are meant to ensure that all transactions are authorized, recorded and reported correctly.

During the period under review, there is no material or serious observations have been noticed for inefficiency or inadequacy of such controls.

Further, details of internal financial control and its adequacy are included in the Management Discussion and Analysis Report which is appended as Annexure IV and forms part of this Report.

31. INSURANCE

The properties and assets of your Company are adequately insured.

32. CREDIT & GUARANTEE FACILITIES

The Company has not availed credit and guarantee facilities.

33. RISK MANAGEMENT POLICY

Business Risk Evaluation and Management is an ongoing process within the Organization. The Company has a robust risk management framework to identify, monitor and minimize risks and also to identify business opportunities. As a process, the risks associated with the business are identified and prioritized based on severity, likelihood and effectiveness of current detection. Such risks are reviewed by the senior management on a quarterly basis.

Risk Management Committee of the Board of Directors of your Company assists the Board in (a) overseeing and approving the Company's enterprise wide risk management framework; and (b) overseeing that all the risks that the organization faces such as strategic, financial, credit, market, liquidity, security, property, IT, legal, regulatory, reputational, other risks have been identified and assessed, and there is an adequate risk management infrastructure in place capable of addressing those risks. The development and implementation of risk management policy has been covered in the Management Discussion and Analysis, which forms part of this Report.

34. SHARE CAPITAL

The authorized share capital of the Company stands at Rs.16,00,00,000/- divided into 1,60,00,000 equity shares of Rs.10/- each.

The paid up share capital of the Company stands at Rs. 14,80,87,060/- divided into 1,48,08,706 equity shares of Rs.10/- each.

35. CORPORATE GOVERNANCE AND SHAREHOLDERS INFORMATION:

The Company has implemented all of its major stipulations as applicable to the Company. As stipulated under Regulation 34 read with schedule V of SEBI (LODR) Regulations, 2015, a report on Corporate Governance duly audited is appended as Annexure V for information of the Members. A requisite certificate from the Secretarial Auditors of the Company confirming compliance with the conditions of Corporate Governance is attached to the Report on Corporate Governance.

36. MANAGEMENT DISCUSSIONS AND ANALYSIS REPORT:

The Management Discussion and Analysis Report, pursuant to the SEBI (LODR) Regulation provides an overview of the affairs of the Company, its legal status and autonomy, business environment, mission & objectives, sectoral and operational performance, strengths, opportunities, constraints, strategy and risks and concerns, as well as human resource and internal control systems is appended as Annexure IV for information of the Members.

37. POLICIES:

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All the policies are available on our website www.drhlsl.com.

38. ENVIRONMENTS AND HUMAN RESOURCE DEVELOPMENT:

Your Company always believes in keeping the environment pollution free and is fully committed to its social responsibility. The Company has been taking utmost care in complying with all pollution control measures from time to time strictly as per the directions of the Government.

We would like to place on record our appreciation for the efforts made by the management and the keen interest shown by the Employees of your Company in this regard.

39. STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliance with regard to the affairs of the Company in all respects.

40. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaint Committee (ICC) has been set up to redress complaints received regarding sexual harassment.

41. STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE AS PER RULE 5(2) & (3) OF THE COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:

A table containing the particulars in accordance with the provisions of Section 197(12) of the Act, read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is appended as Annexure VI(a) to this Report.

A statement showing the names of the top ten employees in terms of remuneration drawn and the name of every employee is annexed to this Annual report as Annexure VI(b).

During the year, NONE of the employees is drawing a remuneration of Rs.1,02,00,000/- and above per annum or Rs.8,50,000/- and above in aggregate per month, the limits specified under the Section 197(12) of the Companies Act, 2013 read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

42. RATIO OF REMUNERATION TO EACH DIRECTOR

Under section 197(12) of the Companies Act, 2013, and Rule 5(1) (2) & (3) of the Companies (Appointment & Remuneration) Rules, 2014 read with Schedule V of the Companies Act, 2013 the ratio of remuneration of (Mr K. Krishnam Raju), Executive Chairman and Whole time director of the Company to the median remuneration of the employees is 59.94:1 respectively.

43. CODE OF CONDUCT COMPLIANCE:

All Members of the Board and Senior Management have affirmed compliance to the Code of Conduct for the Financial Year 2020-21. A declaration signed by the Executive chairman and Whole time Director affirming compliance with the Company's Code of Conduct by the Board of Directors and Senior Management for the Financial Year 2020-21 as required under Regulation 26(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is included in the Corporate Governance Report which is appended as Annexure V and forms part of this Report.

44. MECHANISM FOR EVALUATION OF THE BOARD:

Evaluation of all Board members is performed on an annual basis. The evaluation is performed by the Board, Nomination and Remuneration Committee and Independent Directors with specific focus on the performance and effective functioning of the Board and Individual Directors.

In line with Securities and Exchange Board of India Circular No. SEBI/HO/CFD/CMD/CIR/P/2017/004, dated January 5, 2017 and the Companies Amendment Act, 2017 the Company adopted the recommended criteria by Securities and Exchange Board of India.

The criteria for performance evaluation covers the areas relevant to the functioning of the Board and Board Committees such as its composition, oversight and effectiveness, performance, skills and structure etc.

The evaluation of Board of Directors is performed by the Board after seeking all the inputs from the Directors and the Board Committees by seeking inputs from the Committee members.

The performance evaluation of the individual directors is done by the Nomination and Remuneration Committee.

The performance evaluation of non-independent directors, the Board as a whole and the Chairman is done by a separate meeting of Independent directors after taking inputs from the Executive directors.

45. SECRETARIAL STANDARDS

The Company is in compliance with the applicable secretarial standards.

46. EVENT BASED DISCLOSURES

During the year under review, the Company has not taken up any of the following activities except as mentioned:

1. Issue of sweat equity share: NA
2. Issue of shares with differential rights: NA
3. Issue of shares under employee's stock option scheme: NA
4. Disclosure on purchase by Company or giving of loans by it for purchase of its shares: NA
5. Buy back shares: NA
6. Disclosure about revision: NA
7. Preferential Allotment of Shares: NA

However, the Company has terminated the Collaboration Agreement (CA) with Centre for Liver Research and Diagnostics (CLRD) on 29.06.2021

47. CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (IBC):

There is no application filed for corporate insolvency resolution process, by a financial or operational creditor or by the company itself under the IBC before the NCLT.

48. CEO/CFO CERTIFICATION:

The Executive Chairman and Whole time Director and CFO certification of the financial statements for the year 2020-2021 is annexed in this Annual Report as Annexure VII.

49. ACKNOWLEDGEMENTS:

Your Directors wish to place on record their appreciation of the contribution made by the employees at all levels, to the continued growth and prosperity of your Company. Your Directors also wish to place on record their appreciation of business constituents, banks and other financial institutions and shareholders of the Company for their continued support for the growth of the Company.

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

**Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 29.06.2021**

ANNEXURE I

AOC – 1

Statement containing salient features of the financial statements of Subsidiaries (Pursuant to proviso to sub-section (3) of section 129 read with Rule 5 of the Companies (Accounts) Rules, 2014)

1. Name of the Subsidiary: Krisani Bio Sciences Private Limited
2. Reporting Period: 01.04.2020 to 31.03.2021
3. Reporting Currency: Indian Rupee

*Co. was incorporated on 10.11.2009

Sl. No.	Particulars	Krisani Bio Sciences Private Limited
1.	Share Capital	Authorised – 15,00,00,000 Paid up Capital – 11,43,32,000
2.	Reserves and surplus	(3,21,02,134)
3.	Total Assets	16,68,78,612
4.	Total Liabilities	8,47,23,746
5.	Investments	75,000
6.	Turnover	-
7.	Profit / loss before Taxation	(3,18,755)
8.	Provision for Taxation	(2,49,103)
9.	Profit / loss after Taxation	(69,652)
10.	Proposed Dividend	NIL
11.	% of Shareholding	51.33% (58,68,200 Equity Shares)

The following information shall be furnished at the end of the statement:

1. Names of Subsidiaries which are yet to commence operation: None
2. Names of subsidiaries which have been liquidated or sold during the year: None

ANNEXURE II

FORM MR-3

SECRETARIAL AUDIT REPORT

(Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014
FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2021

To

The Members of

Dr Habeebullah Life Sciences Limited

Hyderabad

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Dr. Habeebullah Life Sciences Limited (hereinafter called "the Company"). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, whereby report that in our opinion, the company has, during the financial year commencing from 1st April, 2020 and ended 31st March, 2021, complied with the statutory provisions listed hereunder and also that the Company has proper Board process and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. We have examined the books, papers, minute books, forms and returns filed and other records maintained by Dr. Habeebullah Life Sciences Limited for the financial year ended 31st March, 2021, according to the provisions of:
 - I. The Companies Act, 2013 (the Act) and the rules made there under;
 - II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
 - III. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under.
 - IV. Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment (FDI) and Overseas Direct Investment and External Commercial Borrowings;
2. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992('SEBI Act'):-
 - i. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **During the year under review, there was no instance to be reported by the Company under SEBI Takeover Code.**
 - ii. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Amended Regulations 2018; **The Company has framed code of conduct for regulating & reporting trading by insiders and for fair disclosure and displayed the same on the Company's website i.e. www.drhlsl.com.**
 - iii. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; Not Applicable as the company has not issued any shares during the year under review;

- iv. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008. **Not Applicable as the Company has not issued any debt securities during the year under review;**
- v. The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review. However the company has Venture Capital and Corporate Investments Private Limited as its Share Transfer Agent.**
- vi. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **Not Applicable as the Company has not delisted/proposed to delist its equity shares from any Stock Exchange during the financial year under review;**
- vii. The Securities and Exchange Board of India (Buy back of Securities) Regulations, 2018: **Not Applicable as the Company has not bought back / proposed to buy-back any of its securities during the year under review.**
- viii. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; **Not applicable as the Company has not offered any shares or granted any options pursuant to any employee benefit scheme during the period under review;**
- ix. Other applicable laws include the following:
 - The Payment of Gratuity Act, 1972
 - Employees Provident Fund and Miscellaneous Provisions Act, 1952
 - Employees State Insurance Act, 1948
 - Income Tax Act, 1961
 - Minimum Wages Act, 1948
 - Payment of Bonus Act, 1965
 - Payment of Wages Act, 1936
 - Goods and Services Tax Act, 2016 and Rules made there under
 - Shops and Establishments Act, 1948
 - Trade License from Greater Hyderabad Municipal Corporation
 - Acts relating to Pharmaceuticals and Bio-Pharma Sector
 - a) Drugs and Cosmetic Act 1940
 - b) T.S. Allopathic Private Medical Care Establishments Registration and Regulation Act, 2002

We have also examined compliance with the applicable clauses of the following:

- I. Secretarial Standards issued by The Institute of Company Secretaries of India.
- II. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 were complied with to the extent applicable.

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, etc. mentioned above including the following:

- a) During the year the Company has conducted 5 meetings of the Board of Directors, 5 meetings of the Audit committee, 2 Meeting of Stakeholder Relationship Committee, 1 meeting of Nomination & remuneration Committee and 1 meeting of Independent Directors. We have also examined compliance with the applicable clauses of the Secretarial Standards issued by the Institute of Company secretaries of India.

- b) As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we report that
- I. The provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:
- External Commercial Borrowings were not attracted by the Company under the financial year under report;
 - Foreign Direct Investment (FDI) was not attracted by the Company under the financial year under report;
 - Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the company under the financial year under report.
- II. As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that:-

- a) The company has a Chief Financial Officer (CFO) namely Mr. Nagavenkata Narendra Kumar Konagalla.
- b) The company has a Company Secretary (CS) and Compliance Officer, Ms. Deepa Rajendra Dudani.
- c) The Company has Internal Auditors namely M/s. Tungala & Co., Chartered Accountants, Hyderabad.

We further report that:-

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors; Non-Executive Directors and Independent Directors. There is no change in the composition of the Board of Directors that took place during the period under review.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

As per the minutes of the meetings duly recorded and signed by the Chairman, the decisions of the Board were unanimous and no dissenting views have been recorded.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period there was no event/action having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines etc.

The compliance by the Company of applicable financial laws like Direct and Indirect tax laws has not been reviewed thoroughly in this audit since the same have been subject to review by statutory financial audit and other designated professionals.

For S.S. Reddy & Associates

Sd/-

**S. Sarveswar Reddy
Proprietor**

**M. No. A12611 C.P. No: 7478
UDIN: A012611C000476118**

**Place: Hyderabad
Date: 17.06.2021**

Annexure-A to Secretarial Audit Report

To

The Members of

Dr Habeebullah Life Sciences Limited

Our report of even date is to be read along with this letter

1. Maintenance of secretarial records is the responsibility of the management of the company. Our responsibility is to express an opinion on the secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices we followed provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial Audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For S.S. Reddy & Associates

Sd/-

**S. Sarveswar Reddy
Proprietor**

**M. No. A12611 C.P. No: 7478
UDIN: A012611C000476118**

**Place: Hyderabad
Date: 17.06.2021**

ANNEXURE III

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto

Related Party Disclosures

a) Names of the related parties and nature of relationship (as per IndAS 24):

Nature of Relationship	Name of Related Party
Key Management Personnel (KMP):	K. Krishnam Raju – Promoter, Whole-time Director & Chairman
	Ms. Deepa Dudani, Company Secretary
	Mr. K.N.V Narendra Kumar, CFO and Whole time Director
	Ms. Neha Kankariya (Resigned w.e.f., 13.02.2021)
Body Corporates	Krisani Bio Sciences Private Limited
	Innovision Life Sciences Pvt Ltd (K. Krishnam Raju Promoter, Whole-time Director & Chairman is director)
	M/s. Centre For Liver Research and Diagnostics (K. Krishnam Raju Promoter, Whole-time Director & Chairman is partner)
Relatives of Key Management Personnel (KMP):	Mrs.K.S.V.Kumari (Person Acting in concert (promoter group))
Directors	Dr.Mohammed Aejaz Habeeb (Non Executive-Promoter Director) (resigned w.e.f., 29.06.2021)
	Dr. Syed Ameer Basha Paspala (Non Executive-Promoter Director) (resigned w.e.f., 29.06.2021)
	Dr. Akka Jyothy (Independent Director) (resigned w.e.f., 02.07.2021)
	Dr.T.V.Rama Krishna Murthy (Independent Director) (resigned w.e.f., 02.07.2021)
	Mr. B. Suryaprakasa Rao (Independent Director)

Transactions with related parties: (Amount in Rs.)

Name of Related Party	Nature of Relation	Nature of Transaction	Year ended	
			31.03.2021	31.03.2020
Mr. K. Krishnam Raju	Key management personnel (KMP)	Remuneration	27,00,000	36,00,000
		Rent	-	50,000
		Demad Loan taken	76,45,000	1,19,90,000
		Demad Loan Repaid	2,39,000	53,30,000
Dr.Mohammed AejazHabeb	Promoter – Non Executive	Professional Fee	-	3,78,509
Dr. Syed Ameer BashaPaspala	Promoter – Non Executive	Professional Fee	51,037	26,19,433
		Demad Loan Taken	-	-
Dr. Akka Jyothy	Independent Director	Sitting fee	75,000	90,000
Dr.T.V.Rama Krishna Murthy	Independent Director	Sitting fee	75,000	1,05,000
Mr.B.Suryaprakasa Rao	Independent Director	Sitting fee	75,000	1,05,000
K.N.V.Narendra Kumar	Chief Financial Officer	Remuneration	5,25,000	8,40,000
Ms.Neha Kankariya	Company Secretary	Remuneration	3,13,928	60,000
Ms.Deepa Dudani	Company Secretary	Remuneration	33,785	-
Innovision Life Sciences Pvt Ltd	(K. Krishnam Raju Promoter, Whole-time Director & Chairman is director)	Interest Income	14,77,331	15,81,825
M/s. Centre For Liver Research and Diagnostics	(K. Krishnam Raju Promoter, Whole-time Director & Chairman is partner)	Lease Deposit	-	-
		Advance	-	70,00,000

M/s. Centre For Liver Research and Diagnostics	(K. Krishnam Raju Promoter, Whole-time Director & Chairman is partner)	Rent Expenses	30,615	33,79,196
K.S.V.Kumari	(Person Acting in concert (promoter group))	Rent	-	1,40,000
		Demand Loan Taken	7,00,000	-

Transactions/balances outstanding with related parties :

Name of Related Party	Nature of Relation	Nature of Transaction	Year ended	
			31.03.2021	31.03.2020
Mr. K. Krishnam Raju	Key management personnel (KMP)	Remuneration	49,50,800	29,25,800
		Rent	3,87,500	3,87,500
		Demad Loan Payable	7,74,46,000	7,00,40,000
Dr.Mohammed AejazHabeb	Promoter – Non Executive	Professional Fee	3,25,337	3,25,337
Dr. Syed Ameer BashaPaspala	Promoter – Non Executive	Professional Fee	39,74,933	39,27,724
		Demad Loan Payable	65,00,000	65,00,000
K.N.V.Narendra Kumar	Chief Financial Officer	Remuneration	11,90,080	6,69,880
Innovision Life Sciences Pvt Ltd	(K. Krishnam Raju Promoter, Whole-time Director & Chairman is director)	Inter-Corporate Loan	94,00,000	94,00,000
Innovision Life Sciences Pvt Ltd	(K. Krishnam Raju Promoter, Whole-time Director & Chairman is director)	Interest Income	37,76,850	24,10,319

M/s. Centre For Liver Research and Diagnostics	(K. Krishnam Raju Promoter, Whole-time Director & Chairman is partner)	Lease Deposit	2,00,00,000	2,00,00,000
		Advance	2,98,22,681	2,98,22,681
M/s. Centre For Liver Research and Diagnostics	(K. Krishnam Raju Promoter, Whole-time Director & Chairman is partner)	Rent Expenses	46,491	17,822
K.S.V.Kumari	(Person Acting in concert (promoter group))	Rent	6,44,000	6,44,000
		Demand Loan Payable	1,00,00,000	93,00,000

ANNEXURE IV

MANAGEMENT DISCUSSION AND ANALYSIS

INDUSTRY STRUCTURE AND DEVELOPMENTS:

GLOBAL PHARMACEUTICAL INDUSTRY:

The pharmaceutical industry is at the centre of the fight against the global COVID-19 pandemic and has contributed significantly in terms of supply of critical medications for treatment as well as in developing and manufacturing COVID-19 vaccines. The industry has ensured continuity of supplies of all other medicines to meet the needs of patients across the world.

The global pharmaceutical market size in 2020 was estimated at IS\$ 1.27 Trillion and is expected to expand at a compounded annual growth rate (CAGR) of 3-6% to US\$ 1.6 Trillion by 2025.

The factors driving global medicines spending will be sustained growth in the pharma emerging markets and the consistent launch of high-end specialty innovative products in developed markets. However, slower growth across developed markets due to losses of patent exclusivity for original brands will be an offsetting factor.

INDIAN PHARMACEUTICAL INDUSTRY:

The Indian pharmaceutical industry is the world's third largest in terms of volume and ranks 11th in terms of value. It is among the faster-growing markets and the largest exporter of generic drugs by volume. Outside of the USA, India has the largest number of USFDA-approved pharmaceutical manufacturing facilities. Going forward, India is likely to maintain a leadership position in the manufacture and supply of high-quality generic medicines as well as a major manufacturer of Covid-19 vaccines.

The Indian Pharmaceutical market recorded ~9.5% CAGR between 2016-20 to reach US\$ 21 Billion. It is expected to grow at 7.5%-10.5% CAGR to US\$ 28-32 Billion by 2025.

SNAPSHOT OF THE COMPANY AND ITS PRODUCTS:

DRHLSL so far has diversified business model with three different high capex oriented segments like 1. Stemcell focused hospitals, 2. Molecular Diagnostics Research & service and New drug discovery. Due to Covid-19 and other reasons the company planning to be a Bio-pharma company includes R&D, Trading, Import & Exports and R&D services of Bioproducts and Pharma products. Indian Pharmaceutical industry is doing well and DRHLSL already in Drug discovery and planning to expand its activities to other segments of pharma like bulk drugs etc.

OUTLOOK:

DRHLSL wish to restrict its business as Biopharma Company and to out from Hospitals and diagnostics business. The Indian pharmaceutical industry is the world's third largest in terms of volume and ranks 11th in terms of value. It is among the faster-growing markets and the largest exporter of generic drugs by volume. Outside of the USA, India has the largest number of USFDA-approved pharmaceutical manufacturing facilities. Going forward, India is likely to maintain a leadership position in the manufacture and supply of high-quality generic medicines as well as a major manufacturer of Covid-19 vaccines.

The Indian Pharmaceutical market recorded ~9.5% CAGR between 2016-20 to reach US\$ 21 Billion. It is expected to grow at 7.5%-10.5% CAGR to US\$ 28-32 Billion by 2025.

The outlook of Indian pharma industry is expected to be good for the next one decade; DRHLS expands its R&D division into manufacturing and trading of bio-pharma products.

RISKS AND CONCERNS

The Company is committed to conducting business in accordance with all applicable statutory laws and regulations, and pursuing its core organizational values.

The Company's business model is a bilateral approach. It focuses on striking a balance between the high value creation divisions like Stem cell therapy, new drug discovery on one hand and daily revenue generating divisions like Molecular Diagnostics on the other. This is aimed at minimizing the risk and maximizing the shareholder wealth.

DRHLSL acknowledges that its research and development, manufacture and sale of products and services may face several challenges such as human capital risk, risk of failure or delay of R&D products in a timely manner, risk arising out of strategic co-development arrangements with a partner, changing global and national political and regulatory landscape amongst others. Although the comprehensive eradication of risks associated with the business of the Company is unfeasible, constant efforts are made to analyze their potential impact, assess the changes to risk environment and define actions to mitigate their adverse impact.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

DRHLSL strongly believes that a robust internal control mechanism is a prerequisite to ensure that an organization functions ethically, complies with all legal and regulatory requirements and observes the generally accepted principles of good corporate governance. To enable this, the Company has established a strong internal control system for the Company, which is comprised of policies, guidelines and procedures to ensure the orderly and efficient financial and business conduct.

DRHLSL has adopted strong internal control systems backed by constant reviews and up-gradation. Internal Audit, Statutory Audit by external agencies and the Audit Committee, look into the internal control aspects and further advice on the corrective measures as and when required.

DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

The management discussion and Analysis given below relates to the Audited Financial Statements of Dr. Habeebullah Life Sciences Limited. The discussion should be read in conjunction with the financial statements and related notes for the year ended 31st March 2021.

Summary:

The revenue from the core segment of the business, aggregated to INR 0.13 million in FY 20-21. Combined with a non-operating income of INR 1.48 million, the Revenue for the year ended 31st March 2021, totaled to INR 1.61 million.

The Company has generated revenue from its out-patient hospital facility and its Diagnostic services division during FY 20-21. The revenue generating equipment like MRI, CT Scan, Ultra Sound and X-ray have been bought into complete operation supported by brand awareness and efficient tie-ups with concerned parties.

MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS FRONT, INCLUDING NUMBER OF PEOPLE EMPLOYED.

DRHLSL's employees are the backbone of the Company. It is their knowledge, scientific skills and innovative capabilities that enable DRHLSL to harness the power of science and serve its clients. DRHLSL recognizes that an inclusive culture which promotes diversity, ethics and integrity is crucial. Through a range of HR- led initiatives, we offer customized training programs to enhance the staff's scientific and leadership skills with special attention to collaborative learning amongst the several teams.

FINANCIAL RATIOS

Financial Ratios	FY 2020-21		FY 2019-20		Remarks	
	<i>Standalone</i>	<i>Consolidated</i>	<i>Standalone</i>	<i>Consolidated</i>	<i>Standalone</i>	<i>Consolidated</i>
Debtors Turnover Ratio	0.08	0.08	0.73	0.73	Reduced due to shutting down of operations because of Covid-19	Reduced due to shutting down of operations because of Covid-19
Inventory Turnover Ratio	1.24	1.24	12.12	12.12	Reduced due to shutting down of operations because of Covid-19	Reduced due to shutting down of operations because of Covid-19
Interest Coverage Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	1.28	0.49	1.57	0.52	Reduced due to shutting down of operations because of Covid-19	Reduced due to shutting down of operations because of Covid-19
Debt Equity Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Operating Profit Margin	-385%	-388%	-117%	-122%	Reduced due to shutting down of operations because of Covid-19	Reduced due to shutting down of operations because of Covid-19
Net Profit Margin	-391%	-396%	-118%	-123%	Reduced due to shutting down of operations because of Covid-19	Reduced due to shutting down of operations because of Covid-19

RETURN ON NET WORTH

There is a change in the Return on Net Worth which is at -4.29% for the Financial Year 2020-21 as compared to immediately previous year 2019-20 which was at -13.26%. Reasons for negative increase were due to shutdown of the operations during the financial year because of Covid.19.

DISCLOSURE OF ACCOUNTING TREATMENT

Financial Statements are prepared as per Ind AS duly following the principles laid in the Ind AS. Management has not adopted any other standards other than the prescribed Accounting Standards in preparing the financial statements.

CAUTIONARY STATEMENT/ DISCLAIMER CLAUSE

Certain statements in the Management Discussion and Analysis describing the Company's objectives, predictions may be "forward-looking statements" within the meaning of applicable laws and regulations. Actual results may vary significantly from the forward-looking statements contained in this document due to various risks and uncertainties. These risks and uncertainties include the effect of economic and political conditions in India, new regulations and Government policies that may impact the Company's business as well as its ability to implement the strategy. The Company does not undertake to update this statement.

ANNEXURE V

CORPORATE GOVERNANCE

In accordance with Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the report containing the details of Corporate Governance systems and processes at Dr Habeebullah Life Sciences Limited as follows:

DATE OF REPORT:

The information provided in the Report on Corporate Governance for the purpose of unanimity is as on 31st March, 2021. The Report is updated wherever applicable.

1. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE:

The Company's philosophy on Corporate Governance is backed by Principles of Concern, Commitment, Ethics, Excellence and Learning in all its acts and relationships with Stakeholders, Clients, Associates and Community at large. This philosophy revolves around fair and transparent governance and disclosure practices in line with the principles of Good Corporate Governance. The Corporate Governance Structure in the Company assigns responsibilities and entrusts authority among different participants in the organization viz. the Board of Directors, the Senior Management, Employees, etc. The Company believes that good Corporate Governance is a continuous process and strives to improve the Corporate Governance practices to meet shareholder's expectations.

2. BOARD DIVERSITY:

The Company recognizes and embraces the importance of a diverse board in its success. We believe that a truly diverse board will leverage differences in thought, perspective, knowledge, skill, regional and industry experience, cultural and geographical background, age, ethnicity, race and gender, which will help us, retain our competitive advantage. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors. The Board Diversity Policy is available on our website, www.drhlsl.com.

3. COMPOSITION OF THE BOARD:

The composition of the Board of Directors of the company is an appropriate combination of executive and non-executive Directors with right element of independence. As on March 31st, 2021, the Company's Board comprised of six Directors, out of which three are promoter Directors. In addition, there are three independent Directors including one woman director on the Board. In terms of clause 17(1) (b) of SEBI (LODR) Regulations, 2015, the company is required to have one half of total Directors as independent Directors. The non-executive Directors are appointed or re-appointed based on the recommendation of the Nomination & Remuneration Committee which considers their overall experience, expertise and industry knowledge. One third of the non-executive Directors other than independent Directors, are liable to retire by rotation every year and are eligible for reappointment, subject to approval by the shareholders.

4. ATTENDANCE AND DIRECTORSHIPS HELD:

As mandated by the SEBI (LODR) Regulations, 2015, none of the Directors are members of more than ten Board-level committees nor are they chairman of more than five committees in which they are members. Further all the Directors have confirmed that they do not serve as an independent director in more than seven listed companies or where they are whole-time directors in any listed company, they do not serve as independent director in more than three listed companies.

The names and categories of the Directors on the Board, their attendance at Board meeting during the year and at last Annual General Meeting, as also the number of Directorships and Committee memberships held by them in other companies are shown in Table 1.

Name of Director	Relation ship with another Director	Category	No. of Meeti ngs Held	No. of Meetin gs Attend ed	Wheth er Atten ded Last AGM	No. of <u>Outside</u> Directorship of Companies and chairmanship		No. of other Committee positions in other Companies	
						Chair man	Director	Cha irman	Member
K. Krishnam Raju	NA	Promoter Executive Director	5	5	Yes	-	1.Innovision Life Sciences Private Limited 2. Krisani Bio Sciences Private Limited	-	-
*Mohammed Aeja z Habeeb	NA	Promoter Non-Executive - Non Independent Director	5	5	Yes	-	-	-	-
*Syed Ameer Basha Paspala	NA	Promoter Non-Executive - Non Independent Director	5	5	Yes	-	1. Krisani Bio Sciences Private Limited	-	-
**AkkaJyothy	NA	Non-Executive - Independent Director	5	5	Yes	-	-	-	-
**T.V. Rama Krishna Murthy	NA	Non-Executive - Independent Director	5	5	Yes	-	-	-	-
Suryaprakasa Rao Bom misetti	NA	Non-Executive - Independent Director	5	5	Yes	-	1.Mehu Developers Private Limited 2.Surya Realtors LLP	-	-
^Aakanksha Shukla	NA	Non-Executive - Independent Director	-	-	NA	-	1.Palred Technologies Limited	1	3
^Y. Rama Mohan Reddy	NA	Non-Executive - Independent Director	-	-	NA	-	1.Taaza International Limited 2.G.R.cables Limited 3.Sankhya Infotech Limited	3	7
^^A.S.S.V. Srinivas	NA	Non-Executive - Independent Director	-	-	NA	-	1. Krisani Bio Sciences Private Limited 2. Innovision Life Sciences Private Limited	-	-
^^K.N.V. Narendra Kumar	NA	Whole time director &CFO	-	-	NA	-	-	-	-

The Name of other listed entities where directors of the company are directors and the category of directorship are shown in Table 2.

Name of Director	Name of listed entities in which the concerned Director is a Director	Category of Directorship
K. Krishnam Raju	NIL	NIL
*Mohammed AejazHabeeb	NIL	NIL
*Syed Ameer BashaPaspala	NIL	NIL
**AkkaJyothy	NIL	NIL
**T.V. Rama Krishna Murthy	NIL	NIL
Suryaprakasa Rao Bommiseti	NIL	NIL
^Aakanksha Shukla	1.Palred Technologies Limited	Independent Director
^Y. Rama Mohan Reddy	1.Taaza International Limited 2.G.R.cables Limited 3.Sankhya Infotech Limited	Whole time Director Independent Director Independent Director
^^A.S.S.V. Srinivas	NIL	NIL
^^K.N.V. Narendra Kumar	NIL	NIL

*Resigned w.e.f. 29.06.2021

**Resigned w.e.f 02.07.2021

^Appointed w.e.f 29.06.2021

^^Appointed w.e.f 02.07.2021

Details of Skills/Expertise/Competence matrix of the Board of Directors:

S. No	Name of the Director	Skills/Expertise/Competence in specific functional areas
1.	K. Krishnam Raju	CA
2.	*Mohammed AejazHabeeb	M.D (General Medicine), DM (Gastroenterology) Ph D in Bio-Technology
3.	*Syed Ameer BashaPaspala	Ph D (Bio-Technology), M.Ch (Neurosurgery)
4.	**AkkaJyothy	M.Sc, Ph.D
5.	**T.V. Rama Krishna Murthy	MBBS
6.	Suryaprakasa Rao Bommiseti	CA, Audit, Account, Finance, Banking
7.	^Aakanksha Shukla	PCS
8.	^Y. Rama Mohan Reddy	Graduate
9.	^^A.S.S.V. Srinivas	Post Graduate, Ph.D
10	^^K.N.V. Narendra Kumar	Graduate

*Resigned w.e.f. 29.06.2021

**Resigned w.e.f 02.07.2021

^Appointed w.e.f 29.06.2021

^^Appointed w.e.f 02.07.2021

5. Number of shares and convertible instruments held by non-executive directors;

As on date, none of the Non-Executive directors of the company holds any Equity Shares in the company.

6. COMMITTEES OF THE BOARD:

The Company has four Board-level Committees - Audit Committee, Stakeholder Relationship Committee, Nomination & Remuneration Committee and Independent Directors Committee.

All decisions pertaining to the constitution of Committees, appointment of members and fixing of terms of service for Committee members are taken by the Board of Directors. Details on the role and composition of these Committees, including the number of meetings held during the financial year and the related attendance are provided in this report below.

7. AUDIT COMMITTEE:**A. BRIEF DESCRIPTION OF TERMS OF REFERENCE: -** A qualified and independent Audit Committee has been set up by the Board and the role of the Audit Committee is as under:

- i. Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- ii. Recommending the appointment and removal of External Auditors, fixation of audit fee and approval for payment for any other services;
- iii. Reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding Rs. 100 Crores or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision.
- iv. Review with the management and statutory auditors of the annual financial statements before submission to the Board with particular reference to:
 - (a) Matters required to be included in the directors' responsibility statement to be included in the board's report in terms of clause (c) of sub-section (3) of Section 134 of the Act;
 - (b) Changes, if any, in accounting policies and practices and reasons for the same;
 - (c) Major accounting entries involving estimates based on the exercise of judgment by management;
 - (d) Significant adjustments made in the financial statements arising out of audit findings;
 - (e) Compliance with listing and other legal requirements relating to financial statements;
 - (f) Disclosure of any related party transactions;
 - (g) Modified opinion(s) in the draft audit report;
- v. Review of the quarterly and half yearly financial results with the management before submission to the board for approval;
- vi. reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the board to take up steps in this matter;
- vii. Review and monitor statutory auditor's independence and performance and effectiveness of audit process;
- viii. Approval or any subsequent modification of transactions with related parties;
- ix. Scrutiny of inter-corporate loans and investments;
- x. Review of valuation of undertakings or assets of the company wherever it is necessary;

- xi. Evaluation of internal financial controls and risk management systems;
- xii. Review with the management, statutory auditors and the internal auditors about the nature and scope of audits and of the adequacy of internal control systems;
- xiii. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure, coverage and frequency of internal audit;
- xiv. discussion with internal auditors of any significant findings and follow up there on;
- xv. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- xvi. discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- xvii. Look into the reasons for any substantial defaults in payment to the depositors, debenture-holders, shareholders (in case of non-payment of declared dividend) and creditors, if any;
- xviii. Review the functioning of the whistle blower mechanism;
- xix. Approval of appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate
- xx. Review of the following information:
 - (a) Management discussion and analysis of financial condition and results of operations;
 - (b) Statement of significant related party transactions (as defined by the audit committee), submitted by management;
 - (c) Management letters / letters of internal control weaknesses issued by the statutory auditors;
 - (d) Internal audit reports relating to internal control weaknesses;
 - (e) The appointment, removal and terms of remuneration of the Chief Internal Auditor;
 - (f) Statement of deviations:
 - Quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1) of the Listing Regulations.
 - Annual statement of funds utilized for purposes other than those stated in the offer document/prospectus in terms of Regulation 32(7) of the Listing Regulations.
- xxi. Carrying out any other function as may be referred to the Committee by the Board.
- xxii. Authority to review / investigate into any matter covered by Section 177 of the Companies Act, 2013 and matters specified in Part C of Schedule II of the Listing Regulations.

B. COMPOSITION, MEETINGS & ATTENDANCE:

There were five (5) Audit Committee Meetings held during the year i.e., on 29.07.2020, 14.09.2020, 13.11.2020, 02.12.2020 and 13.02.2021

The Composition of the Committee is as follows:

Name	Designation	Category	No of Meetings held	No of Meetings attended
Mr. Suryaprakasa Rao Bommiseti	Chairman	NED(I)	5	5
*Mr. T.V. Rama Krishna Murthy	Member	NED(I)	5	5
*Ms. AkkaJyothy	Member	NED (I)	5	5
**Mr. Syed Ameer BashaPaspala	Member	NED (P)	5	5
^Dr. A.S.S.V.Srinivas	Member	NED(I)	-	-
^^Mr. Y. Rama Mohan Reddy	Member	NED(I)	-	-

*Resigned w.e.f. 02.07.2021

**Resigned w.e.f. 29.06.2021

^Appointed w.e.f. 02.07.2021

^^Appointed w.e.f. 29.06.2021

NED (I) : Non-Executive Independent Director

NED (P) : Non-Executive Promoter Director

8. NOMINATION AND REMUNERATION COMMITTEE:

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:

The Nomination and Remuneration Committee set up by the Board is responsible for:

- formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy, relating to the remuneration for the directors, key managerial personnel and other employees.
- formulation of the criteria for evaluation of performance of independent directors and the board of directors.
- devising a policy on diversity of board of directors.
- identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board of Directors their appointment and removal.
- whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of Independent Directors.
- recommending to the Board, remuneration, payable to senior management.
- such other matters as may be specified by the Board from time to time.
- Authority to review / investigate into any matter covered by Section 178 of the Companies Act, 2013 and matters specified in Part D of Schedule II of the Listing Regulations.

B. COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR:

There was one (1) Nomination and Remuneration Committee Meeting held during the year i.e., on 13.02.2021

The Composition of the Committee is as follows:

Name	Designation	Category	No of Meetings held	No of Meetings attended
*Ms. Akka Jyothy	Chairperson	NED(I)	1	1
*Mr. T.V. Rama Krishna Murthy	Member	NED(I)	1	1
Mr. Suryaprakasa Rao Bommiseti	Member	NED (I)	1	1
^Dr. A.S.S.V.Srinivas	Chairman	NED (I)	-	-
^^Mr. Y. Rama Mohan Reddy	Member	NED (I)	-	-

NED (I) : Non Executive Independent Director

*Resigned w.e.f. 02.07.2021

^ Appointed w.e.f. 02.07.2021

^^ Appointed w.e.f. 29.06.2021

PERFORMANCE EVALUATION CRITERIA FOR INDEPENDENT DIRECTORS:

The performance evaluation criteria for Independent Directors are already mentioned under the head “Board Evaluation” in Directors’ Report.

POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS’ INDEPENDENCE

Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

Terms and References:

2.1 “Director” means a director appointed to the Board of a Company.

2.2 “Nomination and Remuneration Committee means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and Reg. 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2.3 “Independent Director” means a director referred to in sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Policy:

1. The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company’s operations.
2. In evaluating the suitability of individual Board member, the NR Committee may take into account factors, such as:
 - General understanding of the company’s business dynamics, global business and social perspective;
 - Educational and professional background
 - Standing in the profession;
 - Personal and professional ethics, integrity and values;
 - Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.

2.1 The proposed appointee shall also fulfil the following requirements:

- shall possess a Director Identification Number;
- shall not be disqualified under the companies Act, 2013;
- shall endeavor to attend all Board Meeting and Wherever he is appointed as a Committee Member, the Committee Meeting;
- shall abide by the code of Conduct established by the company for Directors and senior Management personnel;
- shall disclose his concern or interest in any company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
- Such other requirements as may be prescribed, from time to time, under the companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and other relevant laws.

3. Criteria of independence

3.1 The Nomination & Remuneration Committee shall assess the independence of Directors at time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.

3.2 The criteria of independence shall be in accordance with guidelines as laid down in companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3.3 The independent Director shall abide by the “code for independent Directors “as specified in Schedule IV to the companies Act, 2013.

4. Other directorships/ committee memberships

4.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance. Accordingly, members should voluntarily limit their directorships in other listed public limited companies in such a way that it does not interfere with their role as director of the company. The NR Committee shall take into account the nature of and the time involved in a director’s service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.

4.2 A Director shall not serve as director in more than 20 companies of which not more than 10 shall be public limited companies.

4.3 A Director shall not serve as an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed company.

4.4 A Director shall not be a member in more than 10 committees or act as chairman of more than 5 committee across all companies in which he holds directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder’s relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under section 8 of the companies Act, 2013 shall be excluded.

9. STAKEHOLDER’S RELATIONSHIP COMMITTEE:

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:

The Committee’s role includes:

- i. Resolving the grievances of the security holders of the Company including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc.;

- ii. Review of measures taken for effective exercise of voting rights by shareholders;
- iii. Review of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent;
- iv. Review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company;
- v. Such other matter as may be specified by the Board from time to time.
- vi. Authority to review / investigate into any matter covered by Section 178 of the Companies Act, 2013 and matters specified in Part D of Schedule II of the Listing Regulations.

B. COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR:

There were two (2) Stakeholders relationship Committee Meeting held during the year i.e., on 29.07.2020 and 13.02.2021

The Composition of the Committee is as follows:

Name	Designation	Category	No of Meetings held	No of Meetings attended
Mr. T.V. Rama Krishna Murthy	Chairman	NED (I)	2	2
Ms. AkkaJyothy	Member	NED(I)	2	2
Mr. Suryaprakasa Rao Bommiseti	Member	NED (I)	2	2
Mohammed AejazHabeeb	Member	NED (P)	2	2
^Dr. A.S.S.V.Srinivas	Member	NED (I)	-	-
^^Mr. Y. Rama Mohan Reddy	Chairman	NED (I)	-	-

NED (I) : Non-Executive Independent Director

NED (P) : Non-Executive Promoter Director

*Resigned w.e.f. 29.06.2021

**Resigned w.e.f. 02.07.2021

^Appointed w.e.f. 02.07.2021

^^Appointed w.e.f. 29.06.2021

C. DETAILS OF COMPLAINTS/REQUESTS RECEIVED, RESOLVED AND PENDING DURING THE YEAR 2020-21:

Opening balance	Received during the year	Resolved during the year	Closing balance
-	-	-	-

D. NAME AND DESIGNATION OF COMPLIANCE OFFICER:

Ms. Neha Kankariya, Company Secretary and Compliance Officer of the company has resigned from the designation of Company Secretary and Compliance Officer on 13.02.2021

Ms. Deepa R Dudani was appointed as Company Secretary and Compliance Officer of the company w.e.f. 13.02.2021

10. PECUNIARY RELATIONSHIP OR TRANSACTIONS OF THE NON-EXECUTIVE DIRECTORS VIS-À-VIS THE LISTED COMPANY:

None of the Non-Executive Directors except Dr. Mohammed Aejaz Habeeb and Dr. Syed Ameer Basha Paspala had any pecuniary relationship or transaction with the company other than the Directors sitting fees.

A. CRITERIA FOR MAKING PAYMENTS TO NON-EXECUTIVE DIRECTORS:**Policy:**

1. Remuneration to Executive Director and key managerial personnel
 - 1.1 The Board on the recommendation of the Nomination and Remuneration (NR) committee shall review and approve the remuneration payable to the Executive Director of the company within the overall limit approved by the shareholders.
 - 1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the company.
 - 1.3 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:
 - (i) Basic pay
 - (ii) Perquisites and Allowances
 - (iii) Stock Options
 - (iv) Commission (Applicable in case of Executive Directors)
 - (v) Retrial benefits
 - 1.4 The Annual plan and Objectives for Executive committee shall be reviewed by the NR committee and Annual performance Bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.
2. Remuneration to Non – Executive Directors
 - 2.1 The Board, on the recommendation of the NR Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders.
 - 2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non- Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.
3. Remuneration to other employees
 - 3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

B. REMUNERATION TO DIRECTORS PAID DURING THE FINANCIAL YEAR 2020-21 AND OTHER DISCLOSURES:

Name of the Director	Salary (Rs)	Sitting Fees (Rs)	Number of shares held	Service Contracts	Stock Option Details	Fixed Component	Performance Based Incentive
K. Krishnam Raju	27,00,000	-	28,99,630	-	-	-	-
*Mohammed AejaZHabeeb	-	-	17,79,124	-	-	-	-
*Syed Ameer Basha Paspala	-	-	16,61,800	-	-	-	-
**AkkaJyothy	-	75,000	-	-	-	-	-
**T.V. Rama Krishna Murthy	-	75,000	-	-	-	-	-
Suryaprakasa Rao Bommiseti	-	75,000	-	-	-	-	-

*Resigned w.e.f. 29.06.2021

**Resigned w.e.f. 02.07.2021

11. REMUNERATION POLICY:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities should and individual performance.

12. ANNUAL GENERAL MEETINGS:**A. LOCATION, DATE AND TIME OF LAST THREE AGMS AND SPECIAL/ORDINARY RESOLUTIONS THEREAT AS UNDER:**

Year	Date	Time	Venue	Special Resolution Passed
2019-20	26.12.2020	11:00 a.m.	Video Conferencing and Audio Visual Means	Yes
2018-19	28.09.2019	10:30 a.m.	2-5-36/CLRD/1, Survey No. 36, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad – 500048, Telangana, India	Yes
2017-18	28.09.2018	10:30 a.m.	2-5-36/CLRD/1, Survey No. 36, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad – 500048, Telangana, India	Yes

B. PASSING OF RESOLUTIONS BY POSTAL BALLOT

There were no resolutions passed by the Company through Postal Ballot during the financial year 2020-21.

13. MEANS OF COMMUNICATION

The Company regularly intimates its financial results, audited/limited reviewed, to the Stock Exchanges, as soon as the same are taken on record/approved.

In terms of the requirements of SEBI (Listing Obligations & Disclosures Requirements), the un-audited financial results as well as audited financial results, shareholding pattern of the Company and Corporate Governance Report are electronically submitted, unless there are technical difficulties and are displayed through Corporate Filing and Dissemination System viz., on www.bseindia.com and www.msei.in. The un-audited financial results as well as audited financial results, shareholding pattern of the Company and Report on Corporate Governance are displayed on www.bseindia.com and www.msei.in.

14. GENERAL SHAREHOLDER INFORMATION:**A. ANNUAL GENERAL MEETING:**

The 25th Annual General Meeting of the Company will be held as per the following schedule:

Day	Wednesday
Date	15.09.2021
Time	09:00 a.m.
Venue	Through Video Conferencing / other audio video means

B. VENUE: FINANCIAL YEAR AND FINANCIAL YEAR CALENDAR 2021-22 (TENTATIVE SCHEDULE)

The financial calendar (tentative) shall be as under:

Financial Year	2021-22
First Quarterly Results	On or before 14.08.2021
Second Quarterly Results	On or before 14.11.2021
Third Quarterly Results	On or before 14.02.2022
Fourth Quarterly Results	On or before 30.05.2022
Annual General Meeting for year ending 31st March, 2022	On or before 30.09.2022

C. DIVIDEND PAYMENT DATE: No Dividend declared for the Financial year 2020-21

BSE Limited P. J. Towers, Dalal Street Mumbai-400001 (Scrip Code: 539267)	Metropolitan Stock Exchange of India Limited Vibgyor Towers, 4th floor, Plot No C 62, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai – 400 098 (Symbol: DRHABEEB)
--	--

The Company has paid the listing fees for the year 2020-21 to BSE and MSEI Ltd, and yet to pay for the FY, 2021-22.

E. STOCK MARKET PRICE DATA:**BSE Ltd**

Month	Open Price (in Rs.)	High Price (in Rs.)	Low Price (in Rs.)	Close Price (inRs.)	No. of Shares Traded
Mar 2021	34.90	48.10	32.90	43.65	12,269
Feb 2021	33.75	39.10	29.60	34.10	5,046
Jan 2021	36.35	46.05	29.70	34.80	8,135
Dec 2020	48.15	50.45	35.35	38.25	1,821
Nov 2020	41.80	53.30	39.95	48.15	421
Oct 2020	49.50	54.00	40.15	44.00	2,757
Sept 2020	59.40	61.75	49.50	49.50	1,162
Aug 2020	42.55	65.55	42.55	58.25	2,850
Jul 2020	54.05	54.05	30.95	44.75	1,852
Jun 2020	54.15	56.85	54.15	56.85	108
May 2020	-	-	-	-	-
April 2020	57.00	57.00	54.15	54.15	1,021

F. REGISTRAR AND SHARE TRANSFER AGENTS:

Venture Capital and Corporate Investments Private Ltd
Address: 12-10-167, Bharat Nagar, Hyderabad – 500 018 Telangana State, India
Ph No. 040-23818475, 23818476
Email: info@vccilindia.com
Website: www.vccipl.com

G. SHARE TRANSFER SYSTEM:

The Company's Shares are permitted to trade on BSE Limited and MSEI Limited compulsorily in the dematerialized form. Transfer of dematerialised shares is done through depositories with no involvement of the Company.

H. DISTRIBUTION OF SHAREHOLDING AS ON 31ST MARCH, 2021:

SL. NO.	Nominal Value	Holders	Holders %	Amount	Amount %
1	Upto - 5000	461	84.28	43012	0.29
2	5001 - 10000	11	2.01	8747	0.06
3	10001 - 20000	10	1.83	14575	0.1
4	20001 - 30000	2	0.37	5733	0.04
5	30001 - 40000	3	0.55	11617	0.08
6	40001 - 50000	5	0.91	24265	0.16
7	50001 - 100000	11	2.01	90582	0.61
8	100001 and above	44	8.04	14610175	98.66
	TOTAL	547	100	14808706	100

I. DEMATERIALISATION & LIQUIDITY OF SHARES:

Trading in Company's shares is permitted only in dematerialized form for all investors. The ISIN allotted to the Company's scrip is **INE579N01018**. Investors are therefore advised to open a demat account with a Depository participant of their choice to trade in dematerialized form. Shares held in demat mode as on March 31, 2021 is as follows:

Particulars	No. of Shares	% Share Capital
NSDL	85,62,106	57.82
CDSL	57,61,600	38.91
Physical	4,85,000	3.27
Total	14,808,706	100.00

J. Outstanding Global Depository Receipts Or American Depository Receipts Or Warrants Or Any Convertible Instruments, Conversion Date And Likely Impact On Equity: NIL

K. Commodity Price Risk Or Foreign Exchange Risk And Hedging Activities: NIL

L. PLANT LOCATIONS: Nil

M. REGISTERED OFFICE AND ADDRESS FOR CORRESPONDANCE:

Dr Habeebullah Life Sciences Limited
Address: 2-5-26/CLRD/1, Survey No. 36, Chintalmet X Roads,
Upperpally, Rajender Nagar Mandal, Hyderabad, 500048, Telangana State, India
Contact: +91 9030057370, 040 2970 3333
E-mail: investorrelations@drhisl.com

N. BOOK CLOSURE DATE:

The date of Book Closure for the purpose of Annual General Meeting shall be from 09.09.2021 to 15.09.2021 (both days inclusive).

O. **ELECTRONIC CONNECTIVITY:** Demat ISIN Number: INE579N01018

P. NATIONAL SECURITIES DEPOSITORY LIMITED

Trade World, Kamala Mills Compound
SenapatiBapat Marg, Lower Parel
Mumbai – 400 013.

Q. CENTRAL DEPOSITORY SERVICES (INDIA) LIMITED

Marathon Futurex, A-Wing,
25th floor, NM Joshi Marg,
Lower Parel, Mumbai 400013

R. SHAREHOLDING PATTERN AS ON 31ST MARCH, 2021:

S. No	Category	No. Shares held	% of shareholding
A	Shareholding of Promoter and Promoter group		
1.	Indian	--	--
	Individual	86,29,030	58.27
	Body Corporate	--	--
2.	Foreign	--	--
	Individual	--	--
	Sub-Total A	86,29,030	58.27
B.	Public Shareholding	--	--
1.	Institutions	--	--
2.	Non-Institutions		
	a. Bodies Corporate	603	0
	b. Indian Public and Others	61,79,073	41.73
	Sub Total B	61,79,676	41.73
	Grand Total (A+B)	1,48,08,706	100

15. OTHER DISCLOSURES:

A. COMPLIANCES: MSEI has imposed a penalty on the Company for delay in submission of voting results of AGM for the year 2018-19 and the company has paid the penalty for the same.

B. DISCLOSURES ON MATERIALLY SIGNIFICANT RELATED PARTY TRANSACTIONS THAT MAY HAVE POTENTIAL CONFLICT WITH THE INTERESTS OF LISTED ENTITY AT LARGE

In line with the requirements of the Companies Act, 2013 and Listing Regulations, your Company has formulated a Policy on Related Party Transactions which is also available on Company's Website www.drhlsl.com. The Policy intends to ensure that proper reporting, approval and disclosure processes are in place for all transactions between the Company and Related Parties.

All Related Party Transactions are placed before the Audit Committee for review and approval. Prior omnibus approval is obtained for Related Party Transactions on a quarterly basis for transactions which are of repetitive nature and / or entered in the Ordinary Course of Business and are at Arm's Length. All Related Party Transactions are subjected to independent review by the statutory auditor to establish compliance with the requirements of Related Party Transactions under the Companies Act, 2013 and Listing Regulations.

All Related Party Transactions entered during the year were in Ordinary Course of the Business and on Arm's Length basis. No Material Related Party Transactions, Accordingly, the disclosure of Related Party Transactions as required under Section 134(3) (h) of the Companies Act, 2013 in Form AOC-1 annexed as Annexure I

C. DISCLOSURE OF PENDING CASES / INSTANCES OF NON-COMPLIANCE:

The Board reviews the compliance of all the applicable laws and gives appropriate directions wherever necessary. There are no pending cases or instances of non compliance.

D. DISCLOSURE IN RELATION TO THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

Particulars	Number
No. of Complaints filed during the financial year	Nil
No. of Complaints disposed of during the financial year	Nil
No. of Complaints pending as on end of the financial year	Nil

E. AUDIT FEES (INCLUDING SUBSIDIARY): Rs. 2,00,000 (excluding GST)**F. DETAILS OF UTILIZATION OF FUNDS RAISED THROUGH PREFERENTIAL ALLOTMENT OR QUALIFIED INSTITUTIONS PLACEMENT AS SPECIFIED UNDER REGULATION 32 (7A): NIL****G. Subsidiary Companies:**

The Company has a material subsidiary as defined under Listing Regulations, how ever, the policy for determining its 'Material' Subsidiaries was formulated and the same is available on the website of the Company www.drhlsl.com

H. COMPLIANCE WITH THE DISCRETIONARY REQUIREMENTS UNDER LISTING REGULATIONS:

The Board of Directors periodically reviewed the compliance of all applicable laws and steps taken by the Company to rectify instances of non-compliance, if any. The Company is in compliance with all mandatory requirements of Listing Regulations. In addition, the Company has also adopted the following non-mandatory requirements to the extent mentioned below:

- Audit qualifications: Company's financial statements have no qualifications.
- Reporting of Internal Auditor: The Internal Auditor of the Company directly reports to the Audit Committee on functional matters.

I. COMPLIANCE WITH GOVERNANCE FRAMEWORK:

The Company has complied with all the mandatory requirements specified in Regulations 17 to 27 and clauses (b) to (i) of sub-regulation (2) of Regulation 46 of the Listing Regulations.

The Company has submitted quarterly compliance report on Corporate Governance with the Stock Exchanges, in accordance with the requirements of Regulation 27(2) (a) of the Listing Regulations.

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

**Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 29.06.2021**

CERTIFICATE ON CORPORATE GOVERNANCE

TO THE MEMBERS OF

DR HABEEBULLAH LIFE SCIENCES LIMITED

We have examined the compliance of the conditions of Corporate Governance by Dr Habeebullah Life Sciences Limited ('the Company') for the year ended on March 31, 2021, as stipulated under Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and para-C, D & E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations').

The compliance of the conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to the review of procedures and implementation thereof, as adopted by the Company for ensuring compliance with conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and the representations made by the Directors and the Management and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India warranted due to the spread of the COVID-19 pandemic, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations for the year ended on March 31, 2021.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

For S.S. Reddy & Associates

Sd/-

S. Sarveswar Reddy

Proprietor

M. No. A12611 C.P. No: 7478

UDIN: A012611C000476118

Place: Hyderabad

Date: 17.06.2021

Practicing Company Secretary's Certificate on Directors

To the Members of **DR Habeebullah Life Sciences Limited**

In my opinion and to the best of my information and according to the explanations given to me, and the representations made by the Directors and the Management of the Company, I certify that none of the Directors on the Board of the Company has been debarred or disqualified from being appointed or continuing as directors of companies by the Board/Ministry of Corporate Affairs or any such statutory authority as on the date of this certificate.

For S.S. Reddy & Associates

Sd/-

**S. Sarveswar Reddy
Proprietor**

**M. No. A12611 C.P. No: 7478
UDIN: A012611C000476118**

**Place: Hyderabad
Date: 17.06.2021**

ANNEXURE – VI

REMUNERATION RATIO OF THE DIRECTORS / KEY MANAGERIAL PERSONNEL (KMP) / EMPLOYEES FOR THE FINANCIAL YEAR 2020-21

A. Statement of Disclosure under Section 197(12) read with Rule 5(1) of The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Companies (Particulars of Employees) Rules, 1975:

- Ratio of remuneration of each Executive Director to the median remuneration of the Employees of the Company and percentage increase in remuneration of Key Managerial Personnel (KMP) and other Executive Directors during the Financial Year 2020-21:

Sl. No	Name	Designation	Remuneration paid FY 2020-21 (In Rs.)	Remuneration paid FY 2019-20 (In Rs.)	% Increase in remuneration from previous years	Ratio/times per median of Directors remuneration
1	Mr. K. Krishnam Raju	Executive Chairman & Whole-time Director	27,00,000	36,00,000	Nil	59.94:1
2	Ms. Pooja Jain	Company Secretary (KMP, resigned w.e.f 13.08.2019)	-	95,967	Nil	NIL
3	Mrs. K. Ramyanka Yadav	Company Secretary (KMP, resigned w.e.f. 18.12.2019)	-	1,35,040	Nil	NIL
4	Ms. Neha Kankaria	Company Secretary (KMP) (Appointed w.e.f 1.2.2020)	3,13,928	60,000	Nil	NIL
5	Ms.K. Nirusha	Chief Financial Officer (KMP, resigned w.e.f. 14.02.2020)	-	7,86,207	Nil	NIL
6	Mr. K.N.V Narendra Kumar	Chief Financial Officer (KMP) (Appointed w.e.f 14.2.2020)	5,25,000	1,40,000	Nil	NIL
7	Ms. Deepa Dudani	Company Secretary (KMP) (Appointed w.e.f 13.2.2021)	33,785	-	Nil	NIL

The ratio of remuneration of Whole time Director cum Chairman (Mr K. Krishnam Raju) of the Company to the median remuneration of the employees is 59.94:1.

1. The Company has 3 employees on the rolls of the Company as on 31st March, 2021.
2. Average percentage reduction made in the salaries of the employees other than the Managerial Personnel in the financial year was NIL whereas the average percentage decrease in the remuneration to the Managerial Personnel NIL
3. Key parameters for any variable component of remuneration availed by the Directors: Not Applicable
4. It is hereby affirmed that the remuneration paid during the year is as per the Remuneration policy.

B. Information as per Rule 5(2) of Chapter XIII of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

1. Top 10 employees of the Company based on Remuneration drawn for FY 2020-21:

S.No	Name of the Employee	Age	Designation	Nature of Employment	Educational Qualification & Experience	Date of Joining	Gross Remuneration	Past Employment
1	K. Krishnam Raju	62	Chairman	Permanent	CA and Entrepreneur & 31 Years	26.12.2016	27,00,000	Krisani Group
2	K.N.V Narendra Kumar	43	CFO	Permanent	B.Com	14.02.2020	5,25,000	Krisani Bio Sciences Pvt.Ltd
3	Neha Kankariya	28	CS	Permanent	CS	01.02.2020	3,13,928	Regency Ceramics Limited
4	Ch. Kalyan Kumar	43	Vice President - Lab Operations	Permanent	Ph.D & 15 Years	01.06.2017	2,10,671	Krisani Bio Sciences Private Limited
5	Sandeep Kumar	34	Scientist	Permanent	Ph.D & 12 Years	01.06.2017	1,85,886	CLRD
6	Avinash Bardia	37	Scientist	Permanent	Ph.D & 9 Years	01.06.2017	1,78,765	CLRD
7	V.Bhavani	38	Scientist	Permanent	Ph.D & 15 Years	01.06.2017	1,36,317	Krisani Bio Sciences Private Limited
8	V.Someswara Rao	58	Accounts & Admin	Permanent	BSC, LLB & 30 Years	01.04.2019	1,11,532	Krisani Bio Sciences Private Limited
9	N.Mohan Reddy	40	Scientist	Permanent	Ph.D & 10 Years	01.06.2017	96,532	Krisani Bio Sciences Private Limited
10	G.Sravan Kumar	38	Admin	Permanent	B.Com, 12 Years	01.06.2017	81,790	Care Hospitals

2. There are no employees who were in receipt of remuneration in excess of INR 1.02 Crores per annum who were employed throughout the financial year.
3. There are no employees who were in receipt of remuneration for any part of the year, at a rate which, in the aggregate, was in excess of INR 8,50,000 per month.

ANNEXURE VII

Certification in respect of Financial Statements and Cash Flow Statement

(Pursuant to Regulation 17 (8) of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015
For the Financial Year ended March 31, 2021

We have reviewed the Financial Statements and the Cash Flow Statement for the year ended 31st March 2021 and we hereby certify and confirm to the best of our knowledge and belief the following:

- a. The Financial Statements and Cash Flow statement do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
- b. The Financial Statements and the Cash Flow Statement together present a true and fair view of the affairs of the Company and are in compliance with existing accounting standards, applicable laws and regulations.
- c. There are no transactions entered in to by the Company during the year ended 31st March 2021 which are fraudulent, illegal or violative of Company's Code of Conduct.
- d. We accept responsibility for establishing and maintaining internal controls for Financial Reporting and we have evaluated the effectiveness of these internal control systems of the Company pertaining to financial reporting. Deficiencies noted, if any, are discussed with the Auditors and Audit Committee, as appropriate, and suitable actions are taken to rectify the same.
- e. There have been no significant changes in the above mentioned internal controls over financial reporting during the relevant period.
- f. That there have been no significant changes in the accounting policies during the relevant period.
- g. We have not noticed any significant fraud particularly those involving the, management or an employee having a significant role in the Company's internal control system over Financial Reporting.

Place: Hyderabad
Date:17.06.2021

Sd/-
K.N.V. Narendra Kumar
Chief Financial Officer (CFO)

Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director

Declaration on Code of Conduct as required by Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

I, K. Krishnam Raju, Executive Chairman and whole-time Director of the Company hereby declare that all the members of Board of Directors and Senior Management Personnel have affirmed compliance with Code of Conduct, as applicable to them, in respect of the financial year 2020-21.

Place: Hyderabad
Date:17.06.2021

Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director

INDEPENDENT AUDITOR'S REPORT

To the Members of Dr Habeebullah Life Sciences Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Dr Habeebullah Life Sciences Limited ("the Company"), which comprise the balance sheet as at March 31, 2021, and the statement of Profit and Loss, statement of changes in equity and statement of Cash Flows for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015 as amended and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, and its loss, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our report.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the Director's report but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions

of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Standalone Financial Statements.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) The Balance Sheet, the Statement of Profit and Loss, the Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account;
 - (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (e) On the basis of the written representations received from the directors as on 31st March, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
 - (f) With respect to the adequacy of the internal financial controls with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure C".
 - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and

- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
3. As required by The Companies (Amendment) Act, 2017, in our opinion, according to information, explanations given to us, the remuneration paid by the Company to its directors is within the limits as prescribed under Section 197 of the Act and the rules thereunder.

For A.M.REDDY & D.R.REDDY
Chartered Accountants
ICAI Firm Registration No. 009068S

D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 21209211AAAABW1130

Place: Hyderabad
Date: 29.06.2021

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF DR HABEEBULLAH LIFE SCIENCES LIMITED**Auditor's Responsibilities for the Audit of the Financial Statements**

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned Scope and timing of the audit and significant audit findings, including any significant deficiencies in Internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are

therefore, the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For A.M.REDDY & D.R.REDDY
Chartered Accountants
ICAI Firm Registration No. 009068S

D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 21209211AAAABW1130

Place: Hyderabad
Date: 29.06.2021

ANNEXURE B TO INDEPENDENT AUDITORS' REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF DR HABEEBULLAH LIFE SCIENCES LIMITED FOR THE YEAR ENDED MARCH 31, 2021

[Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report]

i. In respect of the Company's fixed assets:

- (a) The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets (Property, Plant and Equipment).
 - (b) Fixed assets (Property, Plant and Equipment) have been physically verified by the management during the year and no material discrepancies were identified on such verification.
 - (c) According to the information and explanations given to us, there are no immovable properties, and accordingly, the requirements under paragraph 3(i)(c) of the Order are not applicable to the Company.
- ii. The inventory has been physically verified during the year by the management. In our opinion, the frequency of verification is reasonable. No material discrepancies were noticed on verification between the physical stock and the book records.
 - iii. The Company has granted loans, secured to Innovasion Life Sciences Private Limited covered in the register maintained under section 189 of the Act.
 - (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the rate of interest and other terms and conditions on which the loans have been granted to the Company listed in the register maintained under Section 189 of the Act are not, prima facie, prejudicial to the interest of the Company.
 - (b) In case of the loans granted to the Company listed in the register maintained under section 189 of the Act, schedule of repayment of principal and payment of interest have been stipulated. However, the parties have not repaid the principal amount as stipulated and have also not been regular in the payment of interest to the Company.
 - (c) The According to the information and explanations given to us and on the basis of our examination of the records of the Company, the details of amount overdue for more than ninety days are as follows:

No. of Cases	Principal amount overdue	Interest overdue	Total overdue	Remarks (specify whether reasonable steps have been taken by the Company for recovery of principal amount and interest)
1	94,00,000	37,76,850	1,31,76,850	Company is discussing with Borrower to recover the loan.

- iv. In our opinion and according to the information and explanations given to us, the Company has not either directly or indirectly, granted any loan to any of its directors or to any other person in whom the director is interested, in accordance with the provisions of section 185 of the Act and the Company has not made investments through more than two layers of investment companies in accordance with the provisions of section 186 of the Act. Accordingly, provisions stated in paragraph 3(iv) of the Order are not applicable to the Company.
- v. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from the public within the meaning of Sections 73, 74, 75 and 76 of the Act and the rules framed there under. Accordingly, provisions stated in paragraph 3(v) of the Order are not applicable to the Company.
- vi. The provisions of sub-section (1) of section 148 of the Act are not applicable to the Company as the Central Government of India has not specified the maintenance of cost records for any of the products of the Company. Accordingly, the provisions stated in paragraph 3 (vi) of the Order are not applicable to the Company.

- vii. According to the information and explanations given to us, in respect of statutory dues:
- (a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, undisputed statutory dues including provident fund, employees' state insurance, income-tax, goods and service tax, cess and other statutory dues have not been regularly deposited with the appropriate authorities and there have been serious delays in large number of cases.
- (b) According to the information and explanations given to us, undisputed dues in respect of provident fund, employees' state insurance, income-tax, goods and service tax, cess and other statutory dues which were outstanding, at the year end, for a period of more than six months from the date they became payable.

Statutory dues which were outstanding, as at March 31, 2021 for a period of more than six months from the date they became payable are as follows:

Name of the statute	Nature of the dues	TDS Liability (Amount in Rs)	Interest Liability on TDS (Amount in Rs)	Period to which the amount relates	Date of Payment	Remarks, if any
Income Tax Act, 1961	Tax Deductible at Source under Sec 194I	3,07,320	87,930	Financial Year 2019-20 & 20-21	Not paid	TDS has been Outstanding from April-2019 to March-21
	Tax Deductible at Source under Sec 194C	88,285	21,957	Financial Year 2019-20 & 20-21	Not paid	
	Tax Deductible at Source under Sec 192B	23,72,745	5,46,497	Financial Year 2019-20 & 20-21	Not paid	
	Tax Deductible at Source under Sec 194J	8,56,898	2,33,935	Financial Year 2019-20 & 20-21	Not paid	

- (c) According to the information and explanation given to us and the records of the Company examined by us, there are no dues of income tax, goods and service tax, customs duty, cess and any other statutory dues which have not been deposited on account of any dispute.
- viii. The Company does not have any loans or borrowings from any financial institution, banks, government or debenture holders during the year. Accordingly, the provision stated in paragraph 3(viii) of the Order is not applicable to the Company.
- ix. The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, the provisions stated in paragraph 3 (ix) of the Order are not applicable to the Company.
- x. During the course of our audit, examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of material fraud by the Company or on the Company by its officers or employees.
- xi. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has paid/ provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.
- xii. In our opinion and according to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, the provisions stated in paragraph 3(xii) of the Order are not applicable to the Company.

- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- xiv. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, provisions stated in paragraph 3(xv) of the Order are not applicable to the Company.
- xv. In our opinion, the Company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions stated in paragraph clause 3 (xvi) of the Order are not applicable to the Company.

For A.M.REDDY & D.R.REDDY
Chartered Accountants
ICAI Firm Registration No. 009068S

D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 21209211AAAABW1130

Place: Hyderabad
Date: 29.06.2021

ANNEXURE C**TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF DR HABEEBULLAH LIFE SCIENCES LIMITED**

[Referred to in paragraph 2(f) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report]

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls with reference to standalone financial statements of Dr Habeebullah Life Sciences Limited ("the Company") as of March 31, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI) (the "Guidance Note"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 .

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether internal financial controls with reference to standalone financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the internal financial controls with reference to standalone financial statements and their operating effectiveness. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of internal financial controls with reference to standalone financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to standalone financial statements.

Meaning of Internal Financial Controls with Reference to Standalone Financial Statements

A Company's internal financial control with reference to standalone financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control with reference to standalone financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the standalone financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Standalone Financial Statements

Because of the inherent limitations of internal financial controls with reference to standalone financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to standalone financial statements to future periods are subject to the risk that the internal financial control with reference to standalone financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, internal financial controls with reference to standalone financial statements and such internal financial controls with reference to standalone financial statements were operating effectively as at March 31, 2021, based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

For A.M.REDDY & D.R.REDDY
Chartered Accountants
ICAI Firm Registration No. 009068S

D.Rama Krishna Reddy
Partner
Membership No. 209211
UDIN: 21209211AAAABW1130

Place: Hyderabad
Date: 29.06.2021

BALANCE SHEET AS AT 31st MARCH 2021

(Amount in Rs.)

	PARTICULARS	Note No.	As at March 31, 2021	As at March 31, 2020
I	ASSETS:			
(1)	Non-current assets			
	(a) Property, Plant and Equipment	2	1,78,460	2,74,474
	(b) Intangible Assets under development	3	3,25,95,370	3,03,22,522
	(c) Financial assets			
	(i) Investments	4	4,87,06,060	4,87,06,060
	(ii) Other Financial Assets	5	2,03,98,662	2,04,27,662
(2)	Current assets			
	(a) Inventories	6	12,92,128	13,11,401
	(b) Financial assets			
	(i) Trade receivables	7	2,14,25,710	2,17,51,432
	(ii) Cash and cash equivalents	8	41,317	2,35,061
	(iii) Loans and advances	9	1,34,00,000	1,34,00,000
	(iv) Other financial assets	10	37,76,850	24,10,319
	(c) Other current assets	11	3,04,38,501	3,04,31,328
	TOTAL ASSETS		17,22,53,057	16,92,70,259
II	EQUITY AND LIABILITIES:			
	Equity			
	(a) Equity Share Capital	12	14,80,87,060	14,80,87,060
	(b) Other Equity			
	(i) Reserves and Surplus	13	(3,00,83,066)	(2,37,94,493)
	Liabilities			
(1)	Non Current Liabilities			
	(a) Provisions	14	4,56,345	14,49,744
(2)	Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	15	2,34,05,000	1,79,15,000
	(ii) Trade Payables	16	28,72,255	30,49,904
	(b) Other current liabilities	17	2,75,15,367	2,23,20,004
	(c) Provisions	18	96	2,43,040
	TOTAL EQUITY AND LIABILITIES		17,22,53,057	16,92,70,259
	Significant accounting policies and notes to accounts	1 to 29		

As per our report of even date
For A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No.009068S

(D.Rama Krishna Reddy)
Partner
Membership No. 209211

Place: Hyderabad
Date: 29/06/2021

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH 2021

(Amount in Rs.)

	PARTICULARS	Note No.	Year Ended March 31, 2021	Year Ended March 31, 2020
I	Revenue from operations	19	1,29,724	1,43,18,627
II	Other Income	20	14,77,331	15,81,825
III	Total Income (I+II)		16,07,055	1,59,00,452
IV	Expenses:			
	Cost of raw material and components consumed	21	19,273	22,48,894
	Employee Benefits Expenses	22	33,17,297	1,25,95,765
	Depreciation and amortization expenses	2	96,014	1,08,374
	Other expenses	23	58,71,543	1,98,49,020
	Total Expenses		93,04,127	3,48,02,053
V	Profit before tax (III-IV)		(76,97,072)	(1,89,01,601)
VI	Tax Expenses			
	- Current tax		-	-
	- Deferred tax		-	-
VII	Profit for the period (V-VI)		(76,97,072)	(1,89,01,601)
VIII	Other Comprehensive Income (OCI)			
	i) Items that will not be reclassified to profit & loss		14,08,499	1,84,859
	Other comprehensive income for the year (net of tax)		14,08,499	1,84,859
IX	Total Comprehensive Income (VII+VIII)		(62,88,573)	(1,87,16,742)
X	Earnings per equity share: (Equity shares of par value of Rs.10/- each)			
	- Basic	27	(0.42)	(1.28)
	- Diluted	27	(0.42)	(1.28)
	Significant accounting policies and notes to accounts	1 to 29		

As per our report of even date
For A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No.009068S

(D.Rama Krishna Reddy)
Partner
Membership No. 209211

Place: Hyderabad
Date: 29/06/2021

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st MARCH, 2021

(Amount in Rs.)

PARTICULARS	Year Ended March 31, 2021	Year Ended March 31, 2020
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(62,88,573)	(1,87,16,742)
Adjustment for:		
Depreciation and Amortisation	96,014	1,08,374
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(61,92,559)	(1,86,08,368)
Movements in Working Capital::		
(Increase)/ Decrease in trade receivables	3,25,722	3,71,574
(Increase)/ Decrease in Short Term Loans and Advances	-	-
(Increase)/ Decrease in other Current Assets	(7,173)	(71,89,718)
(Increase)/ Decrease in other other financial Assets	(13,66,531)	(14,23,643)
(Increase)/ Decrease in Inventories	19,273	2,80,777
Increase /(Decrease) in Trade Payables	(1,77,649)	6,50,690
Increase/ (Decrease) in Other current liabilities	51,95,363	1,50,10,500
Increase/ (Decrease) in Current Provisions	(2,42,944)	1,66,566
Change in Working Capital	37,46,061	78,66,746
Changes in non current assets and liabilities		
Decrease/(Increase) in loans & advances	29,000	(1,73,448)
(Decrease)/Increase in Long Term Borrowings	-	-
(Decrease)/Increase in Long Term Provisions	(9,93,399)	1,92,298
Changes in non current assets and liabilities	(9,64,399)	18,850
Cash Generated From Operations	(34,10,897)	(1,07,22,772)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(34,10,897)	(1,07,22,772)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work In progress	(22,72,849)	(88,67,047)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Net cash used in Investing activities (B)	(22,72,849)	(88,67,047)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	1,50,00,000
Increase / (Decrease) in Borrowings	54,90,000	46,75,000
Interest paid	-	-
Net cash Flow from Financing Activities (C)	54,90,000	1,96,75,000
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	(1,93,745)	85,181
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	2,35,061	1,49,880
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	41,317	2,35,061

As per our report of even date
For A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No.009068S

(D.Rama Krishna Reddy)
Partner
Membership No. 209211

Place: Hyderabad
Date: 29/06/2021

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31st MARCH, 2021

a. Equity share capital

(Amount in Rs.)

	Amount
Balance as at the 31 March 2018	11,75,87,060
Changes in equity share capital during 2018-19	2,05,00,000
Balance as at the 31 March 2019	13,80,87,060
Changes in equity share capital during 2019-20	1,00,00,000
Balance as at the 31 March 2020	14,80,87,060
Changes in equity share capital during 2020-21	-
Balance as at the 31 March 2021	14,80,87,060

b. Other equity

(Amount in Rs.)

	Share Warrants	Reserves and surplus		Items of Other comprehensive income (OCI)	Total
		Securities Premium Reserve	Retained earnings	Others	
Balance at 31 March 2019	50,00,000	3,55,00,000	(5,06,41,175)	63,425	(1,00,77,750)
Total Comprehensive Income for the year ended 31 March 2020					
Profit or loss	-	-	(1,89,01,601)	-	(1,89,01,601)
Other comprehensive income(net of tax)	-	-	-	1,84,859	1,84,859
Total comprehensive income	-	-	(1,89,01,601)	1,84,859	(1,87,16,742)
Transactions with owners in their capacity as owners	-	1,00,00,000	-	-	1,00,00,000
Balance at 31 March 2020	50,00,000	4,55,00,000	(6,95,42,776)	2,48,284	(1,87,94,492)
Total Comprehensive income for the year ended 31 March 2021					
Profit or loss	-	-	(76,97,072)	-	(76,97,072)
Other comprehensive income(net of tax)	-	-	-	14,08,499	14,08,499
Total comprehensive income	-	-	(76,97,072)	14,08,499	(62,88,573)
Transactions with owners in their capacity as owners	-	-	-	-	-
Balance at 31 March 2021	-	4,55,00,000	(7,72,39,848)	16,56,783.00	(3,00,83,065)

As per our report of even date
For A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No.009068S

(D.Rama Krishna Reddy)
Partner
Membership No. 209211

Place: Hyderabad
Date: 29/06/2021

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

1. Significant Accounting Policies & Notes annexed to and forming part of the financial Statements

1.1. Basis for preparation of financial statements:

a) Compliance with Indian Accounting Standards (Ind AS)

The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 of the Companies Act, 2013.

The same accounting policies have been applied for all the periods presented except when the company has made use of certain exceptions.

The financial statements have been prepared on the historical cost basis except for certain instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the schedule III of the Act. The Company has determined its operating cycle as twelve months for the purpose of current-noncurrent classification of assets and liabilities.

The financial statements are presented in Indian Rupees which is also its functional currency. All amounts have been rounded – off to the nearest rupees, unless otherwise indicated.

b) Use of estimates and judgment

In preparing these financial statements, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of certain assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.

Estimation of uncertainties relating to the global health pandemic from COVID-19 ("COVID-19")

The Company has considered the possible effects that may result from the pandemic relating to COVID-19 in the preparation of these standalone financial statements including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company has, at the date of approval of these financial statements, used internal and external sources of information including credit reports and related information and economic forecasts and expects that the carrying amount of these assets will be recovered. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of these standalone financial statements.

1.2. Property, Plant and Equipment & Depreciation

Items of Property, Plant and Equipment are stated at cost less accumulated depreciation.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labor, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

Assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less cost of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units).

Depreciation on the fixed assets has been provided based on useful lives as prescribed under part C of the schedule II of the companies' act, 2013.

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

Depreciation on additions (disposals) is provided on a pro-rata basis i.e., from (up to) the date on which asset is ready for use (disposed of).

1.3 Impairment of non-financial assets

The Company's non-financial assets, other than deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit and loss. Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

1.4 Intangible assets

Intangible assets are amortized over the estimated useful lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method are reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as change in accounting estimates. The amortization expense on intangible assets with finite useful lives is recognized in profit or loss.

1.5 Inventory

Cost of inventories have been computed to include all costs of purchases (including materials), cost of conversion and other costs incurred, as the case may be, in bringing the inventories to their present location and condition.

Stores and consumables are valued at cost arrived at on FIFO basis or net realisable value, whichever is lower.

1.6 Foreign currencies transactions and translations

Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency closing rates of exchange at the reporting date.

The gain or loss on decrease/increase in reporting currency due to fluctuations in foreign exchange rates, in case of monetary current assets and liabilities in foreign currency, are recognised in the Statement of Profit and Loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are recorded using the exchange rates at the date of the transaction.

1.7 Provisions

A provision is recognised when the Company has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (other than employee benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

1.8 Revenue Recognition

The Company primarily earns revenue by providing Health care services (Diagnostic & Outpatient Services).

Revenue is recognised when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met as described below.

Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of indirect taxes, trade allowances, rebates and amounts collected on behalf of third parties and is not recognised in instances where there is uncertainty with regard to ultimate collection. In such cases revenue is recognised on reasonable certainty of collection.

Interest Income

Interest income from a financial asset is recognised using effective interest rate method. However, in respect of certain financial assets where it is not probable that the economic benefits associated with the transaction will flow to the entity and amount of revenue cannot be measured reliably, in such cases interest income is not recognised.

1.9 Dividend Income

Dividends will be recognised when the company's right to receive has been established.

1.10 Employee benefits

1.10.1 Short term employee benefits

The undiscounted amount of short-term employee benefits is expected to be paid in exchange for the services rendered by employees are recognised as an expense during the period when the employees render the services.

1.10.2 Defined benefit plans

a) Gratuity

In accordance with the Payment of Gratuity Act, 1972, Company provides for gratuity, a defined retirement plan (the "Gratuity Plan") covering the eligible employees. The Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee salary and the tenure of employment. Liability with regard to the Gratuity Plan are determined by actuarial valuation as per the requirements of IndAS 19 as of the balance sheet date, based upon which, the Company contributes the ascertained liabilities to Insurer.

b) Provident fund

Eligible employees receive benefits from a provident fund, which is a defined contribution plan. Aggregate contributions along with interest thereon is paid at retirement, death, incapacitation or termination of employment. Both the employee and the Company make monthly contributions to the Regional Provident Fund Commissioner equal to a specified percentage of the covered employee's salary.

c) Employee State Insurance Fund

Eligible employees are entitled to receive benefit under employee state insurance fund scheme. The employer makes contribution to the scheme at a predetermined rate of employee's gross salary. The Company has no further obligations under the plan beyond its monthly contributions. These contributions are made to the fund administered and managed by the Government of India. contributions made on a monthly basis which are charged to the Statement of Profit and Loss.

d) Leave encashment

All the employees who have completed their eligible service in the Company are eligible for leave encashment as per policy of the Company and the same is paid to the eligible employee at retirement, death, incapacitation or termination of employment. This amount, as calculated for all the eligible employees, is charged to the Statement of Profit and Loss.

1.11 Tax Expenses

The tax expense for the period comprises current and deferred tax. Tax is recognised in Statement of Profit and Loss, except to the extent that it relates to items recognised in the comprehensive income or in equity. In which case, the tax is also recognised in other comprehensive income or equity.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are off set only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

Deferred tax

Deferred tax is recognised on temporary differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax is also recognised in respect of carried forward tax losses and tax credits.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The carrying amount of deferred tax liabilities and assets are reviewed at the end of each reporting period.

Minimum alternate tax (MAT)

Minimum alternate tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The Company recognizes MAT credit available as an asset only to the extent that there is convincing evidence that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. In the year in which the company recognizes MAT credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternative Tax under the Income-tax Act, 1961, the said asset is created by way of credit to the Statement of Profit and Loss and shown as "MAT Credit Entitlement." The Company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent the company does not have convincing evidence that it will pay normal tax during the specified period.

1.12 Leases

At the date of commencement of the lease, the Company recognizes a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases. For these short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.

As per Ind AS 116, Variable lease payments that do not depend on an index or rate and are not in substance or fixed, such as those based on performance (i.e. percentage of sales) are not included as lease payments and these payments are recognized in the statement of profit or loss in the period in which the event that triggers the payment occurrence.

Hence, the company did not recognize any ROU as the lease agreement does not contain fixed Minimum Lease payments.

1.13 Borrowing costs

Borrowing costs incurred for obtaining assets which takes substantial period to get ready for their intended use are capitalized to the respective assets wherever the costs are directly attributable to such assets and in other cases by applying weighted average cost of borrowings to the expenditure on such assets. Other borrowing costs are treated as expense for the year.

Transaction costs in respect of long-term borrowings are amortized over the tenor of respective loans using effective interest method.

1.14 Earnings per equity share

(i) Basic earnings per share

Basic earnings per share is calculated by dividing:

- The profit attributable to owner of the company.
- By the weighted number of equity shares outstanding during the financial year

(ii) Diluted earnings per share

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of share outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

1.15 Financial Instruments

i. Financial assets

A. Initial recognition and measurement

All financial assets and liabilities are initially recognized at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, which are not at fair value through profit or loss, are adjusted to the fair value on initial recognition.

a) Financial assets carried at amortized cost (AC)

A financial asset is measured at amortized cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

b) Financial assets at fair value through profit or loss (FVTPL)

A Financial asset which is not classified as AC or FVOCI are measured at FVTPL e.g. investments in mutual funds. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss is recognised in profit or loss and presented net in the Statement of Profit and Loss within other gains/(losses) in the period in which it arises.

c) Financial assets at fair value through other comprehensive income (FVTOCI)

A financial asset is measured at FVTOCI if it is held within a business model whose Objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

B. Investments in subsidiaries

The Company has accounted for its investments in subsidiaries at cost and not adjusted to fair value at the end of each reporting period. Cost represents amount paid for acquisition of the said investments.

ii. Financial Liabilities**A. Initial recognition**

All financial liabilities are recognized at fair value.

B. Subsequent measurement

Financial liabilities are carried at amortized cost using the effective interest method. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

NOTE NO 2: PROPERTY, PLANT AND EQUIPMENT

(Amount in Rs.)

	Computers	Furniture and Fixtures	Lab Equipments	Office Equipment	Total
Gross Carrying Balance at 31 March 2018	74,576	-	19,800	1,26,650	2,21,026
Additions	90,017	-	1,15,640	73,179	2,78,836
Disposals	-	-	-	-	-
Balance at 31 March 2019	1,64,593	-	1,35,440	1,99,829	4,99,862
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Balance at 31 March 2020	1,64,593	-	1,35,440	1,99,829	4,99,862
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Balance at 31 March 2021	1,64,593	-	1,35,440	1,99,829	4,99,862
Accumulated depreciation at 31 March 2018	5,682	-	152	16,687	22,521
Depreciation for the year	52,439	-	4,261	37,793	94,493
Balance at 31 March 2019	58,121	-	4,413	54,480	1,17,014
Depreciation for the year	54,864	-	13,544	39,966	1,08,374
Balance at 31 March 2020	1,12,985	-	17,957	94,446	2,25,388
Depreciation for the year	42,504	-	13,544	39,966	96,014
Balance at 31 March 2021	1,55,489	-	31,501	1,34,412	3,21,402
Carrying amounts(net)					
At 31 March 2018	68,894	-	19,648	1,09,963	1,98,505
At 31 March 2019	1,06,472	-	1,31,027	1,45,349	3,82,848
At 31 March 2020	51,608	-	1,17,483	1,05,383	2,74,474
At 31 March 2021	9,104	-	1,03,939	65,417	1,78,460

Notes to accounts

NOTE NO: 3 INTANGIBLE ASSETS UNDER DEVELOPMENT

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Intangible Assets		
Intangible Assets Under Development	3,25,95,370	3,03,22,522
	3,25,95,370	3,03,22,522

NOTE NO: 4 NON CURRENT INVESTMENTS:

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Investment In Subsidiary Company carried at Cost		
Krisani Bio Sciences Private Limited (58,68,200 equity shares of Rs. 10 each subscribed at Rs. 8.3 per share)	4,87,06,060	4,87,06,060
	4,87,06,060	4,87,06,060

NOTE NO: 5 OTHER NON-CURRENT FINANCIAL ASSETS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Security Deposits	2,03,98,662	2,04,27,662
	2,03,98,662	2,04,27,662

NOTE NO: 6 INVENTORIES

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Stores and consumables	12,92,128	13,11,401
	12,92,128	13,11,401

NOTE NO: 7 TRADE RECEIVABLES

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) Outstanding for a period exceeding six months from the date they are due for payment Unsecured, considered good	2,11,25,710	2,12,45,881
(b) Outstanding for a period not exceeding six months Unsecured, considered good	3,00,000	5,05,551
	2,14,25,710	2,17,51,432

NOTE NO: 8 CASH AND CASH EQUIVALENTS:

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) Balance with banks	24,399	1,74,186
(b) Cash on Hand	16,918	60,875
	41,317	2,35,061

NOTE NO: 9 LOANS & ADVANCES

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) Inter Corporate Loan given to group company M/s Innovision Life Sciences Private Limited	94,00,000	94,00,000
(b) Advane give to Subsidiaries	40,00,000	40,00,000
	1,34,00,000	1,34,00,000

NOTE NO: 10 OTHER FINANCIAL ASSETS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Interest receivable On Inter Corporate Loan given to M/s Innovision Life Sciences Pvt. Ltd	37,76,850	24,10,319
	37,76,850	24,10,319

NOTE NO: 11 OTHER CURRENT ASSETS:

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) GST Receivable	31,866	31,866
(b) MAT Credit Entitlement	2,06,409	2,06,409
(c) Advance Tax & TDS	2,89,313	1,78,513
(d) Other Advances	2,99,10,913	3,00,14,540
	3,04,38,501	3,04,31,328

NOTE NO: 12: EQUITY SHARE CAPITAL

PARTICULARS	As At March 31, 2021		As At March 31, 2020	
	Number	Amount in Rs.	Number	Amount in Rs.
Authorised Equity Shares of Rs. 10/- each	1,60,00,000	16,00,00,000	1,60,00,000	16,00,00,000
Issued, Subscribed and Paid up Equity Shares of Rs. 10/- each fully paid up (Refer foot note (a) to (c) below)	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060
Total	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060

Foot note:**(a) Reconciliation of the number of shares outstanding as at March 31,2021 and March 31,2020**

PARTICULARS	As At March 31, 2021		As At March 31, 2020	
	Number	Amount in Rs.	Number	Amount in Rs.
Equity Shares outstanding at the beginning of the year	1,48,08,706	14,80,87,060	1,38,08,706	13,80,87,060
Equity Shares Issued during the year for Cash*	-	-	10,00,000	1,00,00,000
Equity Shares Issued during the year for other than cash	-	-	-	-
Equity Shares bought back during year	-	-	-	-
Equity Shares outstanding at the end of the year	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060

(b) Details of Shareholders holding more than 5 % shares:

PARTICULARS	As At March 31,2021		As At March 31,2020	
	No. of Shares	% of Holding	No. of Shares	% of Holding
1 K. Krishnam Raju	28,99,630	19.58%	28,99,630	19.58%
2 Mohammed Aejaaz Habeeb	17,79,124	12.01%	17,79,124	12.01%
3 Syed Ameer Basha Paspala	16,61,800	11.22%	16,61,800	11.22%
4 K. Sarada Vijaya Kumari	8,65,690	5.85%	8,65,690	5.85%
5 K. Nirusha	10,29,200	6.95%	10,29,200	6.95%
6 P. Parvathi	3,93,586	2.66%	3,93,586	2.66%
7 Arun Kumar Bhangadia (Public)	7,73,728	5.22%	7,73,728	5.22%
8 M. Neela Reddy (Public)	6,93,000	4.68%	6,93,000	4.68%

(c) Terms and rights attached to the equity shares:

The Company has only one class of equity shares having par value of Rs.10/- each. Each holder of equity shares is entitled for one vote per share. Distribution of dividends and repayment of capital, if any, by the company, shall be subject to the provisions of applicable laws.

NOTE NO: 13 RESERVES AND SURPLUS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) Securities Premium:	4,55,00,000	4,55,00,000
(b) Retained earnings:		
Opening balance	(6,95,42,777)	(5,06,41,176)
(+) Net profit during the year	(76,97,072)	(1,89,01,601)
Closing balance	(7,72,39,849)	(6,95,42,777)
(c) Other Comprehensive income:		
Opening balance	2,48,284	63,425
(+) During the year	14,08,499	1,84,859
Closing balance	16,56,783	2,48,284
Total (a+b+c)	(3,00,83,066)	(2,37,94,493)

NOTE NO: 14 LONG TERM PROVISIONS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Provision for employee Gratuity	4,17,577	9,13,733
Provision for Leave Encashment	38,768	5,36,011
	4,56,345	14,49,744

NOTE NO: 15 SHORT TERM BARROWINGS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Un Secured Loans from Unsecured Loans (from promoters) (The above loans are interest free loans and repayable on demand)	2,34,05,000	1,79,15,000
	2,34,05,000	1,79,15,000

NOTE NO: 16 TRADE PAYABLES

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Dues to Micro, Small and Medium Enterprises	-	-
Dues to Others	28,72,255	30,49,904
	28,72,255	30,49,904

NOTE NO: 17 OTHER CURRENT LIABILITIES:

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) Statutory Liabilities	45,15,767	30,80,127
(b) Expenses Payable	79,82,704	75,06,777
(c) Employee Benefits Payable	1,50,16,897	1,17,33,100
	2,75,15,368	2,23,20,004

NOTE NO: 18 Short term Provisions

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Provision for Gratuity Payable	96	2,43,040
	96	2,43,040

NOTE NO: 19 REVENUE FROM OPERATIONS

PARTICULARS	Year ended March 31, 2021	Year ended March 31, 2020
	Amount in Rs.	Amount in Rs.
Revenue from Operations		
Diagnostic Services	1,03,204	1,26,03,967
OP Services	26,520	17,14,660
	1,29,724	1,43,18,627

NOTE NO: 20 OTHER INCOME

PARTICULARS	Year ended March 31, 2021	Year ended March 31, 2020
	Amount in Rs.	Amount in Rs.
Non Operating Income		
Finance Income on Interest on ICD	14,77,331	15,81,825
	14,77,331	15,81,825

NOTE NO: 21 MATERIAL AND COMPONENTS CONSUMED

PARTICULARS	Year ended March 31, 2021	Year ended March 31, 2020
	Amount in Rs.	Amount in Rs.
Inventory at the beginning of the year	13,11,401	15,92,177
Add: Purchases	-	19,68,118
Less: inventory at the end of the year	12,92,128	13,11,401
Cost of raw material and components consumed	19,273	22,48,894

NOTE NO: 22 EMPLOYEE BENEFITS EXPENSES

PARTICULARS	Year ended March 31, 2021	Year ended March 31, 2020
	Amount in Rs.	Amount in Rs.
Salaries & Wages	30,66,896	1,14,49,479
Contribution to PF & ESI	53,700	3,94,612
Gratuity and Leave Encashment	1,82,891	5,43,723
EPF Admin Charges	4,440	24,078
Staff welfare expenses	9,370	1,83,873
Total	33,17,297	1,25,95,765

NOTE NO: 23 OTHER EXPENSES

PARTICULARS	Year ended March 31, 2021	Year ended March 31, 2020
	Amount in Rs.	Amount in Rs.
Rent	32,886	39,61,511
Rates and Taxes	8,24,379	3,44,876
Professional & Consultancy Fee	1,44,537	65,96,458
Auditors remuneration(refer Note below)	2,56,500	2,36,000
Office Maintenance	1,36,236	1,50,945
Printing & Stationery	33,980	2,85,762
Communication Expenses	24,937	97,836
Travelling & Conveyance	36,575	6,74,246
Power & Fuel Expenses	24,61,427	31,48,775
Repairs & Maintenance	33,800	2,08,843
Postage & Courier	1,290	10,030
Bank Charges	26,397	52,808
Advertisement & Business Promotion Expenses	96,568	2,40,822
Diagnostic outsourcing expenses	5,130	8,74,088
Listing Processing & Annual Listing Fees	5,36,900	6,25,400
Registrar & Transfer Fees	84,441	85,609
HK, Security and Hospital Maintenance	8,73,398	18,21,058
Lab Maintenance Expenses	-	65,790
Directors Sitting Fees	2,25,000	2,85,000
Other Expenses	37,162	83,165
Total	58,71,543	1,98,49,020

Note: Payment to Auditors :

As Auditors	2020-21	2019-20
Statutory Audit Fees	75,000	2,00,000

* Statutory Audit fees is exclusive of GST

Note No: 27 Earnings Per Share (EPS)

	As at 31.03.2021	As at 31.03.2020
EPS – Basic		
Net Profit (Loss)	(62,88,573)	(1,87,16,742)
Appropriations	-	-
Net Profit (Loss) Attributable to Share Holders as at 31st March (Numerator)	(62,88,573)	(1,87,16,742)
No of Shares outstanding at the beginning of the year	1,48,08,706	1,38,08,706
No of Shares outstanding at the end of the year	1,48,08,706	1,48,08,706
Adjusted Weighted average number of equity shares of Face Value Rs.10 each (Denominator)	1,48,08,706	1,46,03,788
Nominal Value of Ordinary Shares	10	10
Computation of EPS - Basic (in Rs)	(0.42)	(1.28)
EPS – Diluted		
Net Profit (Loss) Attributable to Share Holders as at 31st March of Face Value Rs.10 each (Numerator)	(62,88,573)	(1,87,16,742)
Adjusted Weighted average number of equity shares	1,48,08,706	1,46,03,788
Weighted average number of equity shares that would be issued on conversion of all Shae Warrants into Equity shares	-	-
Total Weighted average number of equity shares for Diluted EPS (Denominator)	1,48,08,706	1,46,03,788
Nominal Value of Ordinary Shares	10.00	10.00
Computation of EPS - Diluted (in Rs)	(0.42)	(1.28)

Particulars	31-03-2021	31-03-2020
Opening balance	1,48,08,706	1,38,08,706
No of shares allotted	-	10,00,000
Date of allotment		14-06-2019
No of Days outstanding	-	291
Therefore weighted no. of Shares	-	7,95,082
No of shares allotted		
Date of allotment		
No of Days outstanding		
Therefore weighted no. of Shares		
Total No of Weighted equity Shares	1,48,08,706	1,46,03,788

24. Related Party Disclosures

As per Ind AS 24 the disclosure of transactions with the related parties are given below.

a) Related Parties and nature of relationship:

Mr.K. Krishnam Raju	Promoter & Whole-time Director & Chairman
Dr. Mohammed Aejez Habeeb	Promoter & Non - Executive Director
Dr. Syed Ameer Basaha Paspala	Promoter & Non - Executive Director
Dr. Akka Jyothy	Independent Non - Executive Director
Dr. T.V. Rama Krishna Murthy	Independent Non - Executive Director
Mr. Surya Prakasa Rao Bommiseti	Independent Non – Executive Director
Ms.Neha Kankaria	Company Secretary & Compliance Officer (Resigned Wef.13/02/2021)
Ms. Deepa Rajendra Dudani	Company Secretary & Compliance Officer (Appointed on 13/02/2021)
Mr. Nagavenkata Narendra Kumar Konagalla	Chief Financial Officer (KMP)
Krisani Bio Sciences Pvt.Ltd	Subsidiary of Dr Habeebullah Life Sciences Ltd
Mrs. K. Sarada Vijaya Kumari	Promoter Group

The Promoters of DRHLSL are major Promoters and/or Shareholders / Partners of the below entities –

1. Innovision Life Sciences Pvt.Ltd – Company
2. Centre For Liver Research and Diagnostics – Partnership Firm

b) Transactions with Related parties:

Name of the related party	Nature of Transaction	Year ended 31-03-2021 (Rupees)	Year ended 31-03-2020 (Rupees)
K. Krishnam Raju	Remuneration	27,00,000	36,00,000
	Rent expenses	-	50,000
	Demand Loan taken	55,30,000	1,00,05,000
	Demand Loan Repaid	40,000	53,30,000
K.S.V. Kumari	Rent expenses	-	1,40,000
Dr. Mohammed Aejaaz Habeeb	Professional Fee	-	3,78,509
Dr. Syed Ameer Basha Paspala	Professional Fee	51,037	26,19,433
Ms. Pooja Jain	Remuneration	-	95,967
Mrs. K. Nirusha		-	7,86,207
K.N.V. Narendra Kumar	Remuneration	5,25,000	8,40,000
Ms. Neha Kankariya	Remuneration	3,13,928	60,000
Mrs.Ramyanka Yadav	Remuneration	-	1,35,040
Ms. Deepa Rajendra Dudani	Remuneration	33,785	-
CLRD Lease Rental Expense	Rent expenses	30,615	33,79,196
Innovision Life Sciences Pvt. Ltd	Inter-Corporate Loan (given during the year)	-	-
Innovision Life Sciences Pvt. Ltd	Interest Income	14,77,331	15,81,825
Krisani Bio Sciences Pvt. Ltd	Advance	-	-
Centre for Liver Research and Diagnostics	Lease Deposit (paid during the year)	-	-
Centre for Liver Research and Diagnostics	Advance	-	70,00,000

c) Related parties outstanding balances:

Name of the related party	Particulars	As at 31-03-2021 (Rupees)	As at 31-03-2020 (Rupees)
K. Krishnam Raju	Rent payable	3,37,500	3,37,500
	Remuneration payable	49,50,800	29,25,800
	Demand Loan taken	2,34,05,000	1,79,15,000
	Travelling Expenses	16,570	16,570
K.S.V. Kumari	Rent payable	5,94,000	5,94,000
Dr. Mohammed Aejaaz Habeeb	Professional Fee Payable	3,25,337	3,25,337
Dr.Syed Ameer Basha Paspala	Professional Fee Payable	39,74,933	39,27,724
Centre for Liver Research and Diagnostics	Advance (Asset)	2,98,22,681	2,98,22,681
Krisani Bio Sciences Pvt. Ltd	Advance (Asset)	40,00,000	40,00,000
Innovision Life Sciences Pvt. Ltd	Inter-Corporate Loan (Asset)	94,00,000	94,00,000
Innovision Life Sciences Pvt. Ltd	Interest Receivable on Inter-Corporate Loan	37,76,850	24,10,319
K.N.V. Narendra Kumar	Remuneration payable	11,90,080	6,69,880

25. Auditors remuneration:

PARTICULARS	2020-21 (Rupees)	2019-20 (Rupees)
Audit Fee (Exclusive of GST)	75,000	2,00,000
Total	75,000	2,00,000

26. The Board of Directors assesses the financial performance of the Company and makes strategic decisions and has been identified as being the Chief Operating Decision Maker (CODM). Based on the internal reporting provided to the CODM, the Company has only one reportable segment i.e., 'healthcare services which includes hospital, diagnostics, Pharma and Biotechnology (R&D)' and hence no separate disclosures are required under Ind AS 108.

27. Earnings per share (EPS):

The details of number of Equity shares used in calculating Basic and Diluted earnings per share and the EPS are set out below:

PARTICULARS	Year ended 31-03-2021	Year ended 31-03-2020
Weighted average Equity shares for computing Basic EPS	1,48,08,706	1,46,03,788
Dilutive impact of Share Warrants	-	-
Weighted average Equity shares for computing Diluted EPS	1,48,08,706	1,46,03,788
Net Profit (Loss) Attributable to Share Holders as at 31st March	(63,98,265)	(1,87,16,742)
Earnings per Share-Basic	(0.43)	(1.28)
Earnings per Share-Diluted	(0.43)	(1.28)

28. The Company has not received any information from any of the supplier of their being Micro, Small and medium enterprises. Hence, the amounts due to Micro, Small and Medium enterprises outstanding as on 31-03-2021 was Rs. Nil

29. Financial assets

Financial Assets Valuation	Year ended 31-03-2021	Year ended 31-03-2020
Non-Current Investments		
Investment in equity instruments of subsidiaries (cost) Unquoted	487,06,060	487,06,060
Krisani Biosciences Pvt Ltd (5868200 equity shares of Rs 10 each subscribed at Rs. 8.3 per Share)		
Total Investment in subsidiaries	487,06,060	487,06,060
Aggregate book value of quoted investments	-	-
Aggregate market value of quoted investments	-	-
Other Financial Assets (Non-Current)		
Security Deposits at (at amortised cost)	2,03,98,662	2,04,27,662
Total non-current Financial assets	6,91,04,722	6,91,33,722

29.1 Financial Risk Management

In course of its business, the company is exposed to certain financial risk such as market risk (Including currency risk and other price risks), credit risk and liquidity risk that could have significant influence on the company's business and operational/financial performance. The Board of directors reviews and approves risk management framework and policies for managing these risks and monitor suitable mitigating actions taken by the management to minimize potential adverse effects and achieve greater predictability to earnings.

29.2 Credit risk

Credit risk refers to the risk that counterparty will default on its contractual obligations resulting in financial loss to the company. The company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, a means of mitigating the risk of financial loss from defaults.

The company makes an allowance for doubtful debts/advances using expected credit loss model.

29.3 Liquidity risk

Liquidity risk refers to the risk that the company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company's exposure to liquidity risk is minimal.

As per our report of even date
For A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No.009068S

(D.Rama Krishna Reddy)
Partner
Membership No. 209211

Place: Hyderabad
Date: 29/06/2021

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

INDEPENDENT AUDITOR'S REPORT**To the Members of Dr Habeebullah Life Sciences Limited**

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of Dr Habeebullah Life Sciences Limited (hereinafter referred to as the "Holding Company") and its subsidiary (Holding Company and its subsidiary together referred to as "the Group"), which comprise the Consolidated Balance Sheet as at March 31, 2021, and the Consolidated Statement of Profit and Loss, the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows for the year then ended, and notes to the Consolidated Financial Statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, and based on consideration of reports of other auditors on separate financial statements and on the other financial information of subsidiary the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015 as amended and other accounting principles generally accepted in India, of their consolidated state of affairs of the Group, as at March 31, 2021, of consolidated loss, consolidated changes in equity and its consolidated cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in India in terms of the Code of Ethics issued by Institute of Chartered Accountant of India ("ICAI"), and the relevant provisions of the Act and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our report.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the Director's report but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation and presentation of these consolidated financial statements in term of the requirements of the Act that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing ("SAs") will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

We give in "**Annexure A**" a detailed description of Auditor's responsibilities for Audit of the Consolidated Financial Statements.

Other Matters

We did not audit the financial statements of Krisani Bio Sciences Private Limited ("subsidiary"), whose financial statements reflect total assets (before consolidation adjustment) of Rs.16,69,53,612 as at March 31, 2021, total revenues (before consolidation adjustment) are Nil and Cash and cash equivalents (before consolidation adjustment) amounting to Rs.90,568 for the year ended on that date, as considered in the consolidated financial statements. The Consolidated financial statements also include the Group's share of net loss of Rs.69,652 for the year ended March 31, 2021, as considered in the consolidated financial statements, whose financial statements have not been audited by us. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and our report in terms of sub-section (3) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiary, is based solely on the reports of the other auditors.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report, to the extent applicable, that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements;
 - b. In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors;

- c. The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;
- d. In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e. On the basis of the written representations received from the directors of the Holding Company as on March 31, 2021 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary company incorporated in India, none of the directors of the Group company incorporated in India is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
- f. With respect to the adequacy of internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. There were no pending litigations which would impact the consolidated financial position of the Group.
 - ii. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company, and its subsidiary company incorporated in India.
2. As required by The Companies (Amendment) Act, 2017, in our opinion, according to information, explanations given to us, the remuneration paid by the Group to its directors is within the limits laid prescribed under Section 197 of the Act and the rules thereunder.

For A M Reddy & D R Reddy
Chartered Accountants
ICAI Firm Registration No. 009068S

D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 21209211AAAABX1398

Place: Hyderabad
Date: 29/06/2021

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF DR HABEEBULLAH LIFE SCIENCES LIMITED**Auditor's Responsibilities for the Audit of the Consolidated Financial Statements**

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the consolidated financial statements of which we are the independent auditors. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For A M Reddy & D R Reddy
Chartered Accountants
ICAI Firm Registration No. 009068S

D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 21209211AAAABX1398

Place: Hyderabad
Date: 29/06/2021

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF DR HABEEBULLAH LIFE SCIENCES LIMITED

[Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report of even date to the Members of Dr Habeebullah Life Sciences Limited on the consolidated Financial Statements for the year ended March 31, 2021

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended March 31, 2021, we have audited the internal financial controls with reference to consolidated financial statements of Dr Habeebullah Life Sciences Limited (hereinafter referred to as "the Holding Company") and its subsidiary company which is incorporated in India, as of that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding company, its subsidiary company which is incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control with reference to consolidated financial statements criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ("the ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements of the Holding company, its subsidiary company, which is incorporated in India, based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the ICAI and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether internal financial controls with reference to consolidated financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the internal financial controls with reference to consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements of the Holding company, its subsidiary company which is incorporated in India.

Meaning of Internal Financial Controls with Reference to Consolidated Financial Statements

A company's internal financial control with reference to consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of

the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the consolidated financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Consolidated Financial Statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject to the risk that the internal financial control with reference to consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, and to the best of our information and according to the explanations given to us, the Holding Company, its subsidiary company incorporated in India, have, in all material respects, internal financial controls with reference to consolidated financial statements and such internal financial controls with reference to consolidated financial statements were operating effectively as at March 31, 2021, based on the internal control with reference to consolidated financial statements criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

Other Matters

Our aforesaid reports under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to consolidated financial statements insofar as it relates to subsidiary company which is incorporated in India, is based on the corresponding reports of the auditors of such company incorporated in India.

For A M Reddy & D R Reddy
Chartered Accountants
ICAI Firm Registration No. 009068S

D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 21209211AAAABX1398

Place: Hyderabad
Date: 29/06/2021

CONSOLIDATED BALANCE SHEET AS AT 31st MARCH 2021

(Amount in Rs.)

	PARTICULARS	Note No.	As at March 31, 2021	As at March 31, 2020
I	ASSETS:			
(1)	Non-current assets			
	(a) Property, Plant and Equipment	2	5,59,173	13,19,067
	(b) Intangible Assets under development	3	19,39,77,877	18,99,25,539
	(c) Financial assets			
	(i) Investments	4	75,000	75,000
	(ii) Other Financial Assets	5	2,03,98,662	2,04,27,662
	(d) Deferred tax assets (net)	6	48,58,855	46,09,752
(2)	Current assets			
	(a) Inventories	7	12,92,129	13,11,399
	(b) Financial assets			
	(i) Trade receivables	8	2,14,25,710	2,17,51,432
	(ii) Cash and cash equivalents	9	1,31,885	2,94,413
	(iii) Loans and advances	10	94,00,000	94,00,000
	(iv) Other financial assets	11	37,76,850	24,10,319
	(c) Other current assets	12	3,06,04,470	3,05,97,296
	TOTAL ASSETS		28,65,00,611	28,21,21,879
II	EQUITY AND LIABILITIES:			
	Equity			
	(a) Equity Share Capital	13	14,80,87,060	14,80,87,060
	(b) Other Equity			
	(i) Share Warrants	14(a)	-	-
	(ii) Reserves and Surplus	14(b)	(3,65,80,534)	(3,02,56,210)
	(c) Non-Controlling Interests	14(c)	4,00,21,276	4,00,55,175
	Liabilities			
(1)	Non Current Liabilities			
	Financial Liabilities			
	(a) Provisions	15	4,56,345	14,49,744
(2)	Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	16	9,39,46,000	8,58,40,000
	(ii) Trade Payables	17	28,72,255	30,49,903
	(b) Other current liabilities	18	3,76,98,114	3,36,53,168
	(c) Provisions	19	96	2,43,039
	TOTAL EQUITY AND LIABILITIES		28,65,00,611	28,21,21,879
	Significant accounting policies and notes to accounts	1 to 30		

As per our report of even date
For A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No.009068S

(D.Rama Krishna Reddy)
Partner
Membership No. 209211

Place: Hyderabad
Date: 29/06/2021

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH 2021

(Amount in Rs.)

	PARTICULARS	Note No.	Year Ended March 31, 2021	Year Ended March 31, 2020
I	Revenue from operations	20	1,29,724	1,43,18,627
II	Other Income	21	14,77,331	15,81,825
III	Total Income (I+II)		16,07,055	1,59,00,452
IV	Expenses:			
	Cost of raw material and components consumed	22	19,272	22,48,895
	Employee Benefit Expenses	23	34,97,297	1,39,96,215
	Depreciation and amortization expenses	2	1,20,559	1,63,064
	Other expenses	24	59,85,753	2,00,19,591
	Total Expenses		96,22,881	3,64,27,765
V	Profit before tax (III-IV)		(80,15,826)	(2,05,27,313)
VI	Tax Expenses			
	- Current tax		-	-
	- Deferred tax		(2,49,103)	(7,11,011)
VII	Profit for the period (V-VI)		(77,66,723)	(1,98,16,302)
VIII	Other Comprehensive Income (OCI)			
	i) Items that will not be reclassified to profit & loss		14,08,499	1,84,859
	ii) Income tax relating to items that will not be reclassified to profit & loss		-	-
	Other comprehensive income for the year (net of tax)		14,08,499	1,84,859
IX	Total Comprehensive Income (VII+VIII)		(63,58,224)	(1,96,31,443)
X	Comprehensive Income attributable to			
	Owners of the company		(63,24,324)	(1,91,86,259)
	Non Controlling Interest		(33,900)	(4,45,185)
XI	Earnings per equity share: (Equity shares of par value of Rs.10/- each)			
	- Basic	28	(0.43)	(1.31)
	- Diluted	28	(0.43)	(1.31)
	Significant accounting policies and notes to accounts	1 to 30		

As per our report of even date
For A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No.009068S

(D.Rama Krishna Reddy)
Partner
Membership No. 209211

Place: Hyderabad
Date: 29/06/2021

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st, March 2021

(Amount in Rs.)

PARTICULARS	Year Ended March 31, 2021	Year Ended March 31, 2020
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(66,07,327)	(2,05,27,313)
Adjustment for:		
Depreciation and Amortisation	1,20,559	1,63,064
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(64,86,768)	(2,03,64,249)
Movements in Working Capital::		
(Increase)/ Decrease in trade receivables	3,25,722	3,71,574
(Increase) / Decrease in Short term Loans and Advances	-	-
(Increase)/Decrease in other financial assets Assets	(13,66,531)	(14,23,643)
(Increase)/Decrease in other Current Assets	(7,174)	(71,92,416)
(Increase) / Decrease in Inventories	19,270	2,80,779
Increase / (Decrease) in Trade Payables	(1,77,648)	6,50,689
Increase/(Decrease) in Other current liabilities	40,44,946	1,68,51,318
Increase/(Decrease) in Current Provisions	(2,42,943)	1,66,565
Change in Working Capital	25,95,642	97,04,866
Changes in non current assets and liabilities		
Decrease/(Increase) in loans & advances	29,000	(1,73,448)
(Decrease)/Increase in Long Term Provisions	(9,93,399)	3,77,157
Changes in non current assets and liabilities	(9,64,399)	2,03,709
Cash Generated From Operations	(48,55,525)	(1,04,55,674)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(48,55,525)	(1,04,55,674)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work In progress	(34,13,003)	(1,11,39,900)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Net cash used in Investing activities (B)	(34,13,003)	(1,11,39,900)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	1,50,00,000
Increase / (Decrease) in Borrowings	81,06,000	66,60,000
Interest paid	-	-
Net cash Flow from Financing Activities (C)	81,06,000	2,16,60,000
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	(1,62,528)	64,426
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	2,94,414	2,29,988
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	1,31,885	2,94,414

As per our report of even date
For A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No.009068S

(D.Rama Krishna Reddy)
Partner
Membership No. 209211

Place: Hyderabad
Date: 29/06/2021

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31st MARCH, 2021

a. Equity share capital

(Amount in Rs.)

	Amount
Balance as at the 31 March 2018	11,75,87,060
Changes in equity share capital during 2018-19	1,00,00,000
Balance as at the 31 March 2019	12,75,87,060
Changes in equity share capital during 2019-20	1,00,00,000
Balance as at the 31 March 2020	13,75,87,060
Changes in equity share capital during 2020-21	-
Balance as at the 31 March 2021	13,75,87,060

b. Other equity

(Amount in Rs.)

	Share Warrants	Reserves and surplus			Items of Other comprehensive income (OCI)	Equity attributable to the share holders of the company	Non-Controlling Interest	Total
		Securities Premium Reserve	Capital Reserve	Retained earnings	Others			
Balance at 31 March 2019	50,00,000	3,55,00,000	1,75,472	(5,68,08,850)	63,425	(1,60,69,953)	4,05,00,360	2,44,30,407
Total comprehensive income for the year ended 31 March 2020								
Profit or loss	-	-	-	(1,93,71,118)	-	(1,93,71,118)	(4,45,185)	(1,98,16,302)
Other comprehensive income(net of tax)	-	-	-	-	1,84,859	-	-	1,84,859
Total comprehensive income	-	-	-	(1,93,71,118)	1,84,859	(1,91,86,259)	(4,45,185)	(1,96,31,443)
Transactions with owners in their capacity as owners	-	1,00,00,000	-	-	-	1,00,00,000	-	1,00,00,000
Other comprehensive income(net of tax)	-	-	-	-	-	-	-	-
Balance at 31 March 2020	-	4,55,00,000	1,75,472	(7,61,79,968)	2,48,284	(3,02,56,212)	4,00,55,175	97,98,964
Total comprehensive income for the year ended 31 March 2021								
Profit or loss	-	-	-	(77,32,823)	-	(77,32,823)	(33,900)	(77,66,723)
Other comprehensive income(net of tax)	-	-	-	-	14,08,499	-	-	14,08,499
Total comprehensive income	-	-	-	(77,32,823)	14,08,499	(63,24,324)	(33,900)	(63,58,224)
Transactions with owners in their capacity as owners	-	-	-	-	-	-	-	-
Other comprehensive income(net of tax)	-	-	-	-	-	-	-	-
Balance at 31 March 2021	-	4,55,00,000	1,75,472	(8,39,12,790)	16,56,783	(3,65,80,535)	4,00,21,277	34,40,741

As per our report of even date
For A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No.009068S

(D.Rama Krishna Reddy)
Partner
Membership No. 209211

Place: Hyderabad
Date: 29/06/2021

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

Significant Accounting Policies & Notes annexed to and forming part of the Consolidated financial Statements**1.1. Basis for preparation of financial statements:****a) Compliance with Indian Accounting Standards (Ind AS)**

The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 of the Companies Act, 2013.

The same accounting policies have been applied for all the periods presented except when the Group has made use of certain exceptions.

The financial statements have been prepared on the historical cost basis except for certain instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique.

All assets and liabilities have been classified as current or non-current as per the Group normal operating cycle and other criteria set out in the schedule III of the Act. The Group has determined its operating cycle as twelve months for the purpose of current-noncurrent classification of assets and liabilities.

The financial statements are presented in Indian Rupees which is also its functional currency. All amounts have been rounded – off to the nearest rupees, unless otherwise indicated.

b) Basis of consolidation

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries as at 31 March 2021. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.

Specifically, the Group controls an investee if and only if the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee)
- Exposure, or rights, to variable returns from its involvement with the investee, and
- The ability to use its power over the investee to affect its returns the Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control.

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary. The acquisition accounting is used by the group to account for business combinations.

Consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If a member of the group uses accounting policies other than those adopted in the consolidated financial statements for like transactions and events in similar circumstances, appropriate adjustments are made to that group member's financial statements in preparing the consolidated financial statements to ensure conformity with the group's accounting policies.

The financial statements of all entities used for the purpose of consolidation are drawn up to same reporting date as that of the parent company, i.e., year ended on 31st March.

Consolidation procedure

- i. Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognised in the consolidated financial statements at the acquisition date.
- ii. Offset (eliminate) the carrying amount of the parent's investment in each subsidiary and the parent's portion of equity of each subsidiary.
- iii. Eliminate in full intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the group (profits or losses resulting from intragroup transactions that are recognised in assets, such as inventory and fixed assets, are eliminated in full). Intragroup losses may indicate an impairment that requires recognition in the consolidated financial statements. Ind AS 12 Income Taxes applies to temporary differences that arise from the elimination of profits and losses resulting from intragroup transactions.

d) Use of estimates and judgment

In preparing these financial statements, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.

Estimation of uncertainties relating to the global health pandemic from COVID-19 ("COVID-19")

The Company has considered the possible effects that may result from the pandemic relating to COVID-19 in the preparation of these standalone financial statements including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company has, at the date of approval of these financial statements, used internal and external sources of information including credit reports and related information and economic forecasts and expects that the carrying amount of these assets will be recovered. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of these standalone financial statements.

1.2. Property, Plant and Equipment & Depreciation

Items of Property, Plant and Equipment are stated at cost less accumulated depreciation.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labor, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

Assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less cost of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are

largely independent of the cash inflows from other assets or groups of assets (cash-generating units).

Depreciation on the fixed assets has been provided based on useful lives as prescribed under part C of the schedule II of the companies act, 2013.

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (up to) the date on which asset is ready for use (disposed of).

1.3 Impairment of non-financial assets

The Group non-financial assets, other than deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit and loss. Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

1.4 Intangible assets

Intangible assets are amortized over the estimated useful lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method are reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as change in accounting estimates. The amortization expense on intangible assets with finite useful lives is recognized in profit or loss.

1.5 Inventory

Cost of inventories have been computed to include all costs of purchases (including materials), cost of conversion and other costs incurred, as the case may be, in bringing the inventories to their present location and condition.

Stores and consumables are valued at cost arrived at on FIFO basis or net realisable value, whichever is lower.

1.6 Foreign currencies transactions and translations

Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency closing rates of exchange at the reporting date.

The gain or loss on decrease/increase in reporting currency due to fluctuations in foreign exchange rates, in case of monetary current assets and liabilities in foreign currency, are recognised in the Statement of Profit and Loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are recorded using the exchange rates at the date of the transaction.

1.7 Provisions

A provision is recognized when the Group has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (other than employee benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

1.8 Revenue Recognition

The Company primarily earns revenue by providing Health care services (Diagnostic & Outpatient Services).

Revenue is recognised when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met as described below.

Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of indirect taxes, trade allowances, rebates and amounts collected on behalf of third parties and is not recognised in instances where there is uncertainty with regard to ultimate collection. In such cases revenue is recognised on reasonable certainty of collection.

Interest Income

Interest income from a financial asset is recognised using effective interest rate method. However, in respect of certain financial assets where it is not probable that the economic benefits associated with the transaction will flow to the entity and amount of revenue cannot be measured reliably, in such cases interest income is not recognised.

1.9 Dividend Income

Dividends will be recognised when the Group right to receive has been established

1.10 Employee benefits

1.10.1 Short term employee benefits

The undiscounted amount of short-term employee benefits are expected to be paid in exchange for the services rendered by employees are recognised as an expense during the period when the employees render the services.

10.2 Defined benefit plans

a) Gratuity

In accordance with the Payment of Gratuity Act, 1972, Group provides for gratuity, a defined retirement plan (the "Gratuity Plan") covering the eligible employees. The Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee salary and the tenure of employment. Liability with regard to the Gratuity Plan are determined by actuarial valuation as of the balance sheet date, based upon which, the Group contributes the ascertained liabilities to Insurer.

b) Provident fund

Eligible employees receive benefits from a provident fund, which is a defined contribution plan. Aggregate contributions along with interest thereon is paid at retirement, death, incapacitation or termination of employment. Both the employee and the Group make monthly contributions to the Regional Provident Fund Commissioner equal to a specified percentage of the covered employee's salary.

c) Employee State Insurance Fund

Eligible employees are entitled to receive benefit under employee state insurance fund scheme. The employer makes contribution to the scheme at a predetermined rate of employee's gross salary. The Company has no further obligations under the plan beyond its monthly contributions. These

contributions are made to the fund administered and managed by the Government of India. contributions made on a monthly basis which are charged to the Statement of Profit and Loss.

d) Leave encashment

All the employees who have completed their eligible service in the Company are eligible for leave encashment as per policy of the Company and the same is paid to the eligible employee at retirement, death, incapacitation or termination of employment. This amount, as calculated for all the eligible employees, is charged to income and taken as provision in the financial statements.

1.11 Tax Expenses

The tax expense for the period comprises current and deferred tax. Tax is recognised in Statement of Profit and Loss, except to the extent that it relates to items recognised in the comprehensive income or in equity. In which case, the tax is also recognised in other comprehensive income or equity.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are off set only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realize the asset and settle the liability on a net basis or simultaneously.

Deferred tax

Deferred tax is recognised on temporary differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax is also recognised in respect of carried forward tax losses and tax credits.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The carrying amount of deferred tax liabilities and assets are reviewed at the end of each reporting period.

Minimum Alternate Tax (MAT)

Minimum Alternate Tax ('MAT') credit is recognised as an asset only when and to the extent there is convincing evidence that the Company will pay normal income-tax during the specified period. In the year in which the MAT credit becomes eligible to be recognised as an asset, the said asset is created by way of a credit to the statement of profit and loss. The Company reviews the same at each balance sheet date and writes down the carrying amount of MAT credit entitlement to the extent there is no longer convincing evidence to the effect that Company will pay normal income-tax during the specified period.

1.12 Leases

At the date of commencement of the lease, the Company recognizes a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases. For these short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.

As per Ind AS 116, Variable lease payments that do not depend on an index or rate and are not in substance or fixed, such as those based on performance (i.e. percentage of sales) are not included as lease payments and these payments are recognized in the statement of profit or loss in the period in which the event that triggers the payment occurrence.

Hence, the company did not recognize any ROU as the lease agreement does not contain fixed Minimum Lease payments.

1.13 Borrowing costs

Borrowing costs incurred for obtaining assets which takes substantial period to get ready for their intended use are capitalized to the respective assets wherever the costs are directly attributable to such assets and in other cases by applying weighted average cost of borrowings to the expenditure on such assets. Other borrowing costs are treated as expense for the year.

Transaction costs in respect of long-term borrowings are amortized over the tenor of respective loans using effective interest method.

1.14 Earnings per equity share

(i) Basic earnings per share

Basic earnings per share is calculated by dividing:

- The profit attributable to owner of the Group.
- By the weighted number of equity shares outstanding during the financial year

(ii) Diluted earnings per share

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of share outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

1.15 Financial Instruments

i. Financial assets

A. Initial recognition and measurement

All financial assets and liabilities are initially recognized at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, which are not at fair value through profit or loss, are adjusted to the fair value on initial recognition.

a) Financial assets carried at amortized cost (AC)

A financial asset is measured at amortized cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

b) Financial assets at fair value through profit or loss (FVTPL)

A Financial asset which is not classified as AC or FVOCI are measured at FVTPL e.g. investments in mutual funds. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss is recognised in profit or loss and presented net in the Statement of Profit and Loss within other gains/(losses) in the period in which it arises.

c) Financial assets at fair value through other comprehensive income (FVTOCI)

A financial asset is measured at FVTOCI if it is held within a business model whose Objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

B. Investments in subsidiaries

The Group has accounted for its investments in subsidiaries at cost and not adjusted to fair value at the end of each reporting period. Cost represents amount paid for acquisition of the said investments.

ii. Financial Liabilities

A. Initial recognition

All financial liabilities are recognized at fair value.

B. Subsequent measurement

Financial liabilities are carried at amortized cost using the effective interest method. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Consolidated Notes to accounts

NOTE NO 2: PROPERTY, PLANT AND EQUIPMENT

(Amount in Rs.)

	Computers	Furniture and Fixtures	Lab Equipments	Office Equipment	Total
Gross carrying amount Balance at 31 March 2018	7,65,225	5,40,815	89,62,138	4,62,589	1,07,30,767
Additions	90,017	-	1,15,640	73,179	2,78,836
Disposals	-	-	-	-	-
Balance at 31 March 2019	8,55,242	5,40,815	90,77,778	5,35,768	1,10,09,603
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Balance at 31 March 2020	8,55,242	5,40,815	90,77,778	5,35,768	1,10,09,603
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Balance at 31 March 2021	8,55,242	5,40,815	90,77,778	5,35,768	1,10,09,603
Accumulated depreciation at 31 March 2018	6,70,092	3,95,578	56,94,031	3,52,626	71,12,327
Depreciation for the year	78,678	63,681	11,19,627	37,793	12,99,779
Balance at 31 March 2019	7,48,770	4,59,259	68,13,658	3,90,419	84,12,106
Depreciation for the year	54,864	54,690	11,28,910	39,966	12,78,430
Balance at 31 March 2020	8,03,634	5,13,949	79,42,568	4,30,385	96,90,536
Depreciation for the year	42,504	24,545	6,52,879	39,966	7,59,894
Balance at 31 March 2021	8,46,138	5,38,494	85,95,447	4,70,351	1,04,50,430
Carrying amounts(net)					
At 31 March 2018	95,133	1,45,237	32,68,107	1,09,963	36,18,440
At 31 March 2019	1,06,472	81,556	22,64,120	1,45,349	25,97,497
At 31 March 2020	51,608	26,866	11,35,210	1,05,383	13,19,067
At 31 March 2021	9,104	2,321	4,82,331	65,417	5,59,173

Depreciation on Lab Equipments amounting to Rs.6,39,335/- (Previous Year Rs. 6,39,335/-) Included in Intangible Assets Under Development.

Consolidated Notes to accounts

NOTE NO: 3 INTANGIBLE ASSETS UNDER DEVELOPMENT

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Intangible Assets	-	-
Intangible Assets Under Development	19,39,77,877	18,99,25,539
	19,39,77,877	18,99,25,539

NOTE NO: 4 NON CURRENT INVESTMENTS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Investment In Subsidiary Company carried at Cost "Krisani Innovations Private Limited (7,500 Equity Shares of Rs.10 each subscribe at Rs. 10/- per share)"	- 75,000	- 75,000
	75,000	75,000

NOTE NO: 5 OTHER NON-CURRENT FINANCIAL ASSETS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Security Deposits	2,03,98,662	2,04,27,662
	2,03,98,662	2,04,27,662

NOTE NO: 6 DEFERRED TAX ASSETS (Net):

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Opening Deferred Tax asset	46,09,752	38,98,741
Deferred tax asset/(liability) to P&L for the year	2,49,103	7,11,011
Deferred tax asset to OCI for the year	-	-
	48,58,855	46,09,752

Component of Deferred tax asset / (liabilities)

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Deferred tax asset / (liabilities) in relation to:		
Property, plant & equipment	4,15,746	3,31,530
Carry forward Losses	41,49,343	39,84,456
Future allowable Expenses	2,93,766	2,93,766
	48,58,855	46,09,752

NOTE NO: 7 INVENTORIES

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) Stores and consumables	12,92,128	13,11,399
	12,92,128	13,11,399

NOTE NO: 8 TRADE RECEIVABLES

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) Outstanding for a period exceeding six months from the date they are due for payment Unsecured, considered good	2,11,25,710	2,12,45,881
(b) Outstanding for a period not exceeding six months Unsecured, considered good	3,00,000	5,05,551
	2,14,25,710	2,17,51,432

NOTE NO: 9 CASH AND CASH EQUIVALENTS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) Balance with banks	1,06,829	2,30,857
(b) Cash on Hand	25,056	63,556
	1,31,885	2,94,413

NOTE NO: 10 LOANS AND ADVANCES

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Inter Corporate Loan given to group company M/s Innovision Life Sciences Pvt. Ltd	94,00,000	94,00,000
	94,00,000	94,00,000

NOTE NO: 11 OTHER FINANCIAL ASSETS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Interest receivable On Inter Corporate Loan given to M/s Innovision Life Sciences Pvt. Ltd	37,76,850	24,10,319
	37,76,850	24,10,319

NOTE NO: 12 OTHER CURRENT ASSETS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) GST Receivable	1,97,835	1,97,835
(b) MAT Credit Entitlement	2,06,409	2,06,409
('c) Advance Tax & TDS	2,89,313	1,78,513
(d) Other Advances	2,99,10,913	3,00,14,539
	3,06,04,470	3,05,97,296

NOTE NO: 13: EQUITY SHARE CAPITAL

PARTICULARS	As At March 31,2021		As At March 31,2020	
	Number	Amount in Rs.	Number	Amount in Rs.
Authorised Equity Shares of Rs. 10/- each	1,60,00,000	16,00,00,000	1,60,00,000	16,00,00,000
Issued, Subscribed and Paid up Equity Shares of Rs. 10/- each fully paid up (Refer foot note (a) to (c) below)	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060
Total	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060

Foot note:**(a) Reconciliation of the number of shares outstanding as at March 31, 2021 and March 31, 2020:**

PARTICULARS	As At March 31,2021		As At March 31,2020	
	Number	Amount in Rs.	Number	Amount in Rs.
Equity Shares outstanding at the beginning of the year	1,48,08,706	14,80,87,060	1,38,08,706	13,80,87,060
Equity Shares Issued during the year for Cash	-	-	10,00,000	1,00,00,000
Equity Shares Issued during the year for other than cash*	-	-	-	-
Equity Shares bought back during year	-	-	-	-
Equity Shares outstanding at the end of the year	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060

(b) Details of Shareholders holding more than 5% shares :

PARTICULARS	As At March 31,2021		As At March 31,2020	
	No. of Shares	% of Holding	No. of Shares	% of Holding
1 K. Krishnam Raju	28,99,630	19.58%	28,99,630	19.58%
2 Mohammed Aejaz Habeeb	17,79,124	12.01%	17,79,124	12.01%
3 Syed Ameer Basha Paspala	16,61,800	11.22%	16,61,800	11.22%
4 K. Sarada Vijaya Kumari	8,65,690	5.85%	8,65,690	5.85%
5 K. Nirusha	10,29,200	6.95%	10,29,200	6.95%
6 P. Parvathi	3,93,586	2.66%	3,93,586	2.66%
7 Arun Kumar Bhangadia (Public)	7,73,728	5.22%	7,73,728	5.22%
8 M. Neela Reddy (Public)	6,93,000	4.68%	6,93,000	4.68%

(c) Terms and rights attached to the equity shares:

The Company has only one class of equity shares having par value of Rs.10/- each. Each holder of equity shares is entitled for one vote per share. Distribution of dividends and repayment of capital, if any, by the company, shall be subject to the provisions of applicable laws.

NOTE NO: 14 (a) SHARE WARRANTS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Convertible Equity Share Warrants	-	-
	-	-

NOTE NO: 14 (b) RESERVES AND SURPLUS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) Securities Premium:	4,55,00,000	4,55,00,000
(b) Capital Reserve		
Profit on Acquisition of Krisani Bio Sciences Private Limited	1,75,472	1,75,472
(b) Retained earnings:		
Opening balance	(7,61,79,966)	(5,68,08,849)
(+) Net profit during the year	(77,32,823)	(1,93,71,117)
Closing balance	(8,39,12,789)	(7,61,79,966)
(c) Other Comprehensive income:		
Opening balance	2,48,284	63,425
(+) During the year	14,08,499	1,84,859
Closing balance	16,56,783	2,48,284
Total (a+b+c)	(3,65,80,534)	(3,02,56,210)

NOTE NO: 14 (c) NON-CONTROLLING INTERESTS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
NCI % in Krisani Bio Sciences Private Limited	48.67%	48.67%
Non Current Assets	16,66,97,075	16,53,32,362
Current Assets	2,56,537	2,25,320
Non Current Liabilities	-	-
Current Liabilities	(8,47,23,746)	(8,32,58,164)
Net Assets	8,22,29,866	8,22,99,518
Net Assets Attributable to NCI	4,00,21,276	4,00,55,175

NOTE NO: 15 LONG TERM PROVISIONS:

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Provision for employee Gratuity	4,17,577	9,13,733
Provision for Leave encashment	38,768	5,36,011
	4,56,345	14,49,744

NOTE NO: 16 SHORT TERM BARROWINGS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Un Secured Loans from Directors (The above loans are interest free loans and repayable on demand)	9,39,46,000	8,58,40,000
	9,39,46,000	8,58,40,000

NOTE NO: 17 TRADE PAYABLES

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Dues to Micro, Small and Medium Enterprises Dues to others	28,72,255	30,49,902
	28,72,255	30,49,902

NOTE NO: 18 OTHER CURRENT LIABILITIES

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
(a) Statutory Liabilities	92,70,574	30,59,695
(b) Expenses Payable	1,08,22,018	1,83,20,123
(c) Security deposits from customers	25,60,950	34,66,050
(d) Employee Benefits Payable	1,50,44,572	88,07,300
	3,76,98,114	3,36,53,168

NOTE NO: 19 SHORT TERM PROVISIONS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Provision for Gratuity payment	96	2,43,039
	96	2,43,039

NOTE NO: 20 REVENUE FROM OPERATIONS

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Revenue from Operations		
Diagnostic Services	1,03,204	1,26,03,967
OP Services	26,520	17,14,660
Sales - Products	-	-
	1,29,724	1,43,18,627

NOTE NO: 21 OTHER INCOME

PARTICULARS	Year ended March 31, 2021	Year ended March 31, 2020
	Amount in Rs.	Amount in Rs.
Non Operating Income		
Finance Income on		
Interest on ICD	14,77,331	15,81,825
Others	-	-
Liabilities no longer required	-	-
	14,77,331	15,81,825

NOTE NO: 22 MATERIAL AND COMPONENTS CONSUMED

PARTICULARS	Year ended March 31, 2021	Year ended March 31, 2020
	Amount in Rs.	Amount in Rs.
Inventory at the beginning of the year	13,11,400	15,92,177
Add: Purchases	-	19,68,118
Less: inventory at the end of the year	12,92,128	13,11,400
Cost of raw material and components consumed	19,272	22,48,895

NOTE NO: 23 EMPLOYEE BENEFITS EXPENSES

PARTICULARS	Year ended March 31, 2021	Year ended March 31, 2020
	Amount in Rs.	Amount in Rs.
Salaries & Wages	32,46,896	1,28,49,929
Contribution to provident and other funds	53,700	3,94,612
Gratuity and Leave Encashment	1,82,891	5,43,723
EPF Admin Charges	4,440	24,078
Staff welfare expenses	9,370	1,83,873
	34,97,297	1,39,96,215

NOTE NO: 24 OTHER EXPENSES

PARTICULARS	Year ended March 31, 2021	Year ended March 31, 2020
	Amount in Rs.	Amount in Rs.
Rent	32,886	39,61,511
Rates and Taxes	8,44,479	3,64,676
Professional & Consultancy Fee	1,44,537	65,96,458
Auditors remuneration (Refer Note below)	2,86,000	2,65,500
Office Maintenance	1,37,436	1,58,045
Printing & Stationery	34,922	2,87,947
Communication Expenses	24,937	97,836
Travelling & Conveyance	36,575	6,74,246
Power & Fuel Expenses	24,61,427	31,48,775
Repairs & Maintenance	33,800	2,08,843
Postage & Courier	1,290	10,030
Bank Charges	39,212	81,412
Advertisement Expenses	96,568	2,40,822
Diagnostic outsourcing expenses	5,130	8,74,088
Listing Processing & Annual Listing Fees	5,36,900	6,25,400
Registrar & Transfer Fees	84,441	85,609
HK, Security and Hospital Maintenance	8,73,398	18,21,058
Lab Maintenance Expenses	-	65,790
Foreign Exchange loss	49,653	83,382
Directors Sitting Fees	2,25,000	2,85,000
Other Expenses	37,162	83,165
	59,85,753	2,00,19,591

Note: Payment to Auditors :

As Auditors

Statutory Audit Fees

2020-21

1,00,000

2019-20

2,25,000

* Statutory Audit fees is exclusive of GST

Note No: 28 Earnings Per Share (EPS)

	As at 31.03.2021	As at 31.03.2020
EPS – Basic		
Net Profit (Loss)	(63,24,324)	(1,91,86,259)
Appropriations	-	-
Net Profit (Loss) Attributable to Share Holders as at 31st March (Numerator)	(63,24,324)	(1,91,86,259)
No of Shares outstanding at the beginning of the year	1,48,08,706	1,38,08,706
No of Shares outstanding at the end of the year	1,48,08,706	1,48,08,706
Adjusted Weighted average number of equity shares of Face Value Rs.10 each (Denominator)	1,48,08,706	1,46,03,788
Nominal Value of Ordinary Shares	10	10
Computation of EPS - Basic (in Rs)	(0.43)	(1.31)
EPS – Diluted		
Net Profit (Loss) Attributable to Share Holders as at 31st March of Face Value Rs.10 each (Numerator)	(63,24,324)	(1,91,86,259)
Adjusted Weighted average number of equity shares	1,48,08,706	1,46,03,788
Weighted average number of equity shares that would be issued on conversion of all Shae Warrants into Equity shares	-	-
Total Weighted average number of equity shares for Diluted EPS (Denominator)	1,48,08,706	1,46,03,788
Nominal Value of Ordinary Shares	10	10
Computation of EPS - Diluted (in Rs)	(0.43)	(1.31)

Particulars	31-03-2021	31-03-2020
Opening balance	1,48,08,706	1,38,08,706
No of shares allotted		10,00,000
Date of allotment	14-06-2019	14-06-2019
No of Days outstanding	656	291
Therefore weighted no. of Shares	-	7,95,081.97
No of shares allotted		
Date of allotment		
No of Days outstanding		
Therefore weighted no. of Shares		
Total No of Weighted equity Shares	1,48,08,706	1,46,03,788

Particulars	31-03-2021	31-03-2020
Balance of Share Warrants Money	-	-
Full Amount of Share Warrants	-	-
No. of Equity Share to be Issued for warrants	-	-

25. Related Party Disclosures

As per Ind AS 24 the disclosure of transactions with the related parties are given below

a) Related Parties and nature of relationship:

Mr.K. Krishnam Raju	Promoter & Whole-time Director & Chairman
Dr. Mohammed Aejez Habeeb	Promoter & Non – Executive Director
Dr. Syed Ameer Basaha Paspala	Promoter & Non – Executive Director
Dr. Akka Jyothy	Independent Non – Executive Director
Dr.T.V. Rama Krishna Murthy	Independent Non – Executive Director
Mr. Surya Prakasa Rao Bommiseti	Independent Non – Executive Director
Ms.Neha Kankariya	Company Secretary & Compliance Officer (Resigned wef.13/02/2021)
Ms.Deepa Rajendra Dudani	Company Secretary of Subsidiary Company (Appointed on 13/02/2021)
Mr. K.N.V. Narendra Kumar	Chief Financial Officer (KMP)
Mrs.K. Sarada Vijaya Kumari	Director of Subsidiary Company

The Promoters of DRHLSL are major Promoters and/or Shareholders / Partners of the below entities –

1. Innovision Life Sciences Pvt.Ltd – Company
2. Centre For Liver Research and Diagnostics – Partnership Firm

b) Transactions with Related parties:

Name of the related party	Nature of Transaction	Year ended 31-03-2021 (Rupees)	Year ended 31-03-2020 (Rupees)
K. Krishnam Raju	Remuneration	27,00,000	36,00,000
	Rent expenses	-	50,000
	Demand loan taken	76,45,000	1,19,90,000
	Demand loan repaid	2,39,000	53,30,000
K.S.V. Kumari	Rent expenses	-	1,40,000
	Demand loan taken	7,00,000	-
Dr. Mohammed Aejaaz Habeeb	Professional Fee	-	3,78,509
Dr. Syed Ameer Basha Paspala	Professional Fee	51,037	26,19,433
	Demand loan taken	-	--
Ms. Pooja Jain	Remuneration	-	95,967
Mrs. Nirusha	Remuneration	-	7,86,207
Shwetha R Anthapur	Salary paid	1,80,000	2,25,000
K.N.V. Narendra Kumar	Remuneration	5,25,000	8,40,000
Ms. Neha Kankariya	Remuneration	3,13,928	60,000
Ms. Deepa Dudani	Remuneration	33,785	-
Mrs. K. Ramayana Yadav	Remuneration	-	1,35,040
CLRD Lease Rental Expense	Rent expenses	30,615	33,79,196
Innovision Life Sciences Pvt.Ltd	Inter-Corporate Loan	-	-
Innovision Life Sciences Pvt.Ltd	Interest Income	14,77,331	15,81,825
Centre For Liver Research and Diagnostics	Lease Deposit	-	-
Centre For Liver Research and Diagnostics	Advance	-	70,00,000

c) Related parties outstanding balances:

Name of the related party	Particulars	As at 31-03-2021 (Rupees)	As at 31-03-2020 (Rupees)
K. Krishnam Raju	Rent payable	3,87,500	3,87,500
	Remuneration payable	49,50,800	29,25,800
	Demand loan taken	7,74,46,000	7,00,40,000
K.S.V. Kumari	Rent payable	6,44,000	6,44,000
	Demand loan payable	1,00,00,000	93,00,000
Dr. Mohammed Aejaaz Habeeb	Professional Fee Payable	3,25,337	3,25,337
Dr. Syed Ameer Basha Paspala	Professional Fee Payable	39,74,933	39,27,724
	Demand loan payable	65,00,000	65,00,000
Shwetha R Anthapur	Salary payable	-	20,000
Centre for Liver Research and Diagnostics	Advance (Asset)	2,98,22,681	2,98,22,681
Innovision Life Science Limited	Inter-Corporate Loan	94,00,000	94,00,000
Innovision Life Science Limited	Interest Receivable on Inter-Corporate Loan	37,76,850	24,10,319
K.N.V.Narendra Kumar	Remuneration payable	11,90,080	6,69,880

26. Auditors remuneration:

PARTICULARS	2020-21 (Rupees)	2019-20 (Rupees)
Audit Fee (Exclusive of GST)	1,00,000	2,29,500
Total	1,00,000	2,29,500

27. The Board of Directors assesses the financial performance of the Company and make strategic decisions and has been identified as being the Chief Operating Decision Maker (CODM). Based on the internal reporting provided to the CODM, the Company has only one reportable segment i.e. 'healthcare services including hospital, diagnostics, health care skill development and allied services, Pharma and Bio technology (R&D)' and hence no separate disclosures are required under Ind AS 108.

28. Earnings per share (EPS):

The details of number of Equity shares used in calculating Basic and Diluted earnings per share and the EPS are set out below:

PARTICULARS	Year ended 31-03-2021	Year ended 31-03-2020
Weighted average Equity shares for computing Basic EPS	1,48,08,706	1,46,03,788
Dilutive impact of Share Warrants	-	-
Weighted average Equity shares for computing Diluted EPS	1,48,08,706	1,46,03,788
Net Profit (Loss) Attributable to Share Holders as at 31st March	(64,34,016)	(1,91,86,259)
Earnings per Share-Basic	(0.39)	(1.31)
Earnings per Share-Diluted	(0.39)	(1.31)

29. The Group has not received any information from any of the supplier of their being Micro, Small and medium enterprises. Hence, the amounts due to Micro, Small and Medium enterprises outstanding as on 31-03-2021 was Rs. Nil.

30. Financial assets

Financial Assets Valuation	Year ended 31-03-2021	Year ended 31-03-2020
Non-Current Investments		
Investment in equity instruments of other companies (Cost) Unquoted	75,000	75,000
Krisani Innovations Pvt Ltd (7,500 equity shares of Rs 10 each subscribed at Face value)		
Aggregate book value of quoted investments	-	-
Aggregate market value of quoted investments	-	-
Other Financial Assets (Non-Current)		
Security Deposits at (at amortised cost)	2,03,98,662	2,04,27,662
Total non-current Financial assets	2,04,73,662	2,05,02,662

30.1 Financial Risk Management

In course of its business, the Group is exposed to certain financial risk such as market risk (Including currency risk and other price risks), credit risk and liquidity risk that could have significant influence on the Group business and operational/financial performance. The Board of directors reviews and approves risk management framework and policies for managing these risks and monitor suitable mitigating actions taken by the management to minimize potential adverse effects and achieve greater predictability to earnings.

30.2 Credit risk

Credit risk refers to the risk that counterparty will default on its contractual obligations resulting in financial loss to the Group. The Group has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, a means of mitigating the risk of financial loss from defaults.

The Group makes an allowance for doubtful debts/advances using expected credit loss model.

30.3 Liquidity risk

Liquidity risk refers to the risk that the Group cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as pre requirements. The Group exposure to liquidity risk is minimal.

As per our report of even date
For A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No.009068S

(D.Rama Krishna Reddy)
Partner
Membership No. 209211

Place: Hyderabad
Date: 29/06/2021

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

If Undelivered please return to :

DR HABEEBULLAH LIFE SCIENCES LIMITED